##### Table of Contents





UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q



|þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------

FOR THE QUARTERLY PERIOD ENDED June 30, 2009

OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------

FOR THE TRANSITION PERIOD FROM  TO

Commission file number 001-32980

BMP SUNSTONE CORPORATION

(Exact name of registrant as specified in its charter)



|                                                                |  |                                    
|--------------------------------------------------------------- |  | -----------------------------------
|Delaware                                                        |  | 20-0434726                         
|(State or other jurisdiction ofincorporation or organization)   |  | (I.R.S. EmployerIdentification No.)
|                                                                | 
|600 W. Germantown Pike, Suite 400Plymouth Meeting, Pennsylvania |  | 19462                              
|(Address of principal executive offices)                        |  | (Zip Code)                         

(610) 940-1675

(Registrants telephone number, including area code)





(Former name, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.    Yes  þ    No   ̈

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   ̈    No   ̈

Indicate by check mark whether the registrant is
a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in
Rule 12b-2 of the Exchange Act. (Check one):



|                           |  |                      |  |                                               |  |                             
|-------------------------- |  | -------------------- |  | --------------------------------------------- |  | ----------------------------
|Large accelerated filer   ̈ |  | Accelerated filer  þ |  | Non-accelerated filer   ̈                      |  | Smaller reporting company   ̈
|                           |  |                      |  | (Do not check if a smaller reporting company) |  |                             

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).    Yes   ̈    No  þ

The number of shares of common stock of BMP Sunstone Corporation outstanding as of August 7, 2009 was 41,558,905.









---

##### Table of Contents

BMP SUNSTONE CORPORATION

INDEX



|                                                                                                                        |  |        
|----------------------------------------------------------------------------------------------------------------------- |  | -------
|                                                                                                                        |  | PageNo.
|Part I. FINANCIAL INFORMATION                                                                                           |  |        
|Item 1. Financial Statements                                                                                            |  |        
|                                                                                                                        | 
|Condensed Consolidated Balance Sheets as of June 30, 2009 (Unaudited) and December 31, 2008                             |  | 3      
|Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 
30, 2009 and 2008  |  | 4      
|Condensed Consolidated Statements of Stockholders Equity (Unaudited) for the three and six months ended June 
30, 2009 |  | 5      
|Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2009 and
2008             |  | 6      
|Notes to Condensed Consolidated Financial Statements (Unaudited)                                                        |  | 7      
|Item 2. Managements Discussion and Analysis of Financial Condition and Results Of Operations                           |  | 22     
|Item 3. Quantitative and Qualitative Disclosures About Market Risk                                                      |  | 40     
|Item 4. Controls and Procedures                                                                                         |  | 41     
|                                                                                                                        | 
|Part II. OTHER INFORMATION                                                                                              |  |        
|Item 1A. Risk Factors                                                                                                   |  | 42     
|Item 4. Submission of Matters to a Vote of Security Holders                                                             |  | 43     
|Item 6. Exhibits                                                                                                        |  | 44     
|SIGNATURES                                                                                                              |  | 45     
|                                                                                                                        | 
|EX-31.1                                                                                                                 |  |        
|                                                                                                                        | 
|EX-31.2                                                                                                                 |  |        
|                                                                                                                        | 
|EX-32.1                                                                                                                 |  |        
|                                                                                                                        | 
|EX-32.2                                                                                                                 |  |        



2



---

##### Table of Contents

PART I. FINANCIAL INFORMATION



|ITEM 1. | Financial Statements
|------- | --------------------

BMP SUNSTONE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

($ in thousands)



|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ----------------------- | ------- | - | ---------------- | - | ------- | -
|                                                                                                                                                                                                                       |  | (Unaudited)June 30,2009 |         |   | December 31,2008 |  
|Assets                                                                                                                                                                                                                 |  |                         |         |   |                  |   |         |  
|Current Assets:                                                                                                                                                                                                        |  |                         |         |   |                  |   |         |  
|Cash and Cash Equivalents                                                                                                                                                                                              |  | $                       | 8,901   |   |                  | $ | 15,740  |  
|Restricted Cash                                                                                                                                                                                                        |  |                         | 1,563   |   |                  |   | 1,150   |  
|Notes Receivable                                                                                                                                                                                                       |  |                         | 12,905  |   |                  |   | 15,797  |  
|Accounts Receivable, net of allowance for doubtful accounts of $116 and $127                                                                                                                                           |  |                         | 37,770  |   |                  |   | 30,897  |  
|Inventory, net of allowance for obsolescence of $45 and $0                                                                                                                                                             |  |                         | 9,498   |   |                  |   | 10,184  |  
|Due from Related Parties                                                                                                                                                                                               |  |                         | 1,259   |   |                  |   | 1,834   |  
|Other Receivables                                                                                                                                                                                                      |  |                         | 2,091   |   |                  |   | 2,168   |  
|VAT Receivable                                                                                                                                                                                                         |  |                         | 1,141   |   |                  |   | 921     |  
|Prepaid Expenses and Other Current Assets                                                                                                                                                                              |  |                         | 6,683   |   |                  |   | 6,247   |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Total Current Assets                                                                                                                                                                                                   |  |                         | 81,811  |   |                  |   | 84,938  |  
|Property and Equipment, net                                                                                                                                                                                            |  |                         | 23,512  |   |                  |   | 22,840  |  
|Investment in Alliance BMP Limited, at cost                                                                                                                                                                            |  |                         | 15,093  |   |                  |   | 15,093  |  
|Investment in Shengda                                                                                                                                                                                                  |  |                         | 3,003   |   |                  |   |        |  
|Investments at Cost                                                                                                                                                                                                    |  |                         | 146     |   |                  |   | 146     |  
|Goodwill                                                                                                                                                                                                               |  |                         | 69,958  |   |                  |   | 69,866  |  
|Other Assets                                                                                                                                                                                                           |  |                         | 619     |   |                  |   | 875     |  
|Land Use Rights, net accumulated amortization                                                                                                                                                                          |  |                         | 2,869   |   |                  |   | 2,002   |  
|Intangible Assets, net of accumulated amortization                                                                                                                                                                     |  |                         | 40,207  |   |                  |   | 41,891  |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Total Assets                                                                                                                                                                                                           |  | $                       | 237,218 |   |                  | $ | 237,651 |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Liabilities and Equity                                                                                                                                                                                                 |  |                         |         |   |                  |   |         |  
|Current Liabilities:                                                                                                                                                                                                   |  |                         |         |   |                  |   |         |  
|Bank Borrowings                                                                                                                                                                                                        |  | $                       | 1,841   |   |                  | $ | 11,613  |  
|Notes Payable, net of debt discount                                                                                                                                                                                    |  |                         |        |   |                  |   | 21,978  |  
|Accounts Payable                                                                                                                                                                                                       |  |                         | 26,873  |   |                  |   | 27,482  |  
|Due to Related Parties                                                                                                                                                                                                 |  |                         | 2,658   |   |                  |   | 4,361   |  
|Deferred Revenue                                                                                                                                                                                                       |  |                         | 128     |   |                  |   | 128     |  
|Accrued Expenses                                                                                                                                                                                                       |  |                         | 15,201  |   |                  |   | 14,601  |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Total Current Liabilities                                                                                                                                                                                              |  |                         | 46,701  |   |                  |   | 80,163  |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Long-Term Debt, including debt premium                                                                                                                                                                                 |  |                         | 29,641  |   |                  |   |        |  
|Deferred Taxes                                                                                                                                                                                                         |  |                         | 9,646   |   |                  |   | 9,856   |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Total Liabilities                                                                                                                                                                                                      |  |                         | 85,988  |   |                  |   | 90,019  |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Commitments and Contingencies                                                                                                                                                                                          |  |                         |         |   |                  |   |         |  
|                                                                                                                                                                                                                       |  |                        
|Equity:                                                                                                                                                                                                                |  |                         |         |   |                  |   |         |  
|Common Stock, $.001 Par Value; 75,000,000 Shares Authorized as of June 30, 2009 and December 31, 2008; 41,558,905 and 40,246,410
Shares Issued and Outstanding as of June 30, 2009 and December 31, 2008, respectively |  |                         | 42      |   |                  |   | 40      |  
|Additional Paid in Capital                                                                                                                                                                                             |  |                         | 167,578 |   |                  |   | 160,864 |  
|Common Stock Warrants                                                                                                                                                                                                  |  |                         | 8,621   |   |                  |   | 9,049   |  
|Accumulated Deficit                                                                                                                                                                                                    |  |                         | (34,748 | ) |                  |   | (31,042 | )
|Accumulated Other Comprehensive Income                                                                                                                                                                                 |  |                         | 9,314   |   |                  |   | 8,721   |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Total BMP Sunstone Corporation Stockholders Equity                                                                                                                                                                    |  |                         | 150,807 |   |                  |   | 147,632 |  
|Noncontrolling interest                                                                                                                                                                                                |  |                         | 423     |   |                  |   |        |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  
|Total Liabilities and Equity                                                                                                                                                                                           |  | $                       | 237,218 |   |                  | $ | 237,651 |  
|                                                                                                                                                                                                                       |  |                         |         |   |                  |   |         |  

See notes to condensed consolidated financial statements.



3



---

##### Table of Contents

BMP SUNSTONE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

($ in thousands except per share amounts)



|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|---------------------------------------------------------- |  | ----------------------------------- | ------ | - | --------------------------------- | - | ------ | ---- |  | - | ------ | - |  | - | ------ | -
|                                                           |  | For the three months ended June 30, |        |   | For the six months ended June 30, |  
|                                                           |  | 2009                                |        |   | 2008                              |   |        | 2009 |  |   | 2008   |  
|Net Revenues:                                              |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Third Parties                                              |  | $                                   | 32,123 |   |                                   | $ | 27,137 |      |  | $ | 67,644 |   |  | $ | 44,435 |  
|Related Parties                                            |  |                                     | 360    |   |                                   |   | 2,501  |      |  |   | 4,102  |   |  |   | 3,292  |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Total Revenues                                             |  |                                     | 32,483 |   |                                   |   | 29,638 |      |  |   | 71,746 |   |  |   | 47,727 |  
|Cost of Goods Sold                                         |  |                                     | 18,089 |   |                                   |   | 13,077 |      |  |   | 36,694 |   |  |   | 23,445 |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Gross Profit                                               |  |                                     | 14,394 |   |                                   |   | 16,561 |      |  |   | 35,052 |   |  |   | 24,282 |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Sales and Marketing Expenses                               |  |                                     | 10,300 |   |                                   |   | 11,138 |      |  |   | 23,811 |   |  |   | 17,099 |  
|General and Administration Expenses                        |  |                                     | 4,001  |   |                                   |   | 3,819  |      |  |   | 7,930  |   |  |   | 6,975  |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Total Operating Expenses                                   |  |                                     | 14,301 |   |                                   |   | 14,957 |      |  |   | 31,741 |   |  |   | 24,074 |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Profit From Operations                                     |  |                                     | 93     |   |                                   |   | 1,604  |      |  |   | 3,311  |   |  |   | 208    |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Other Income (Expense):                                    |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Interest Income                                            |  |                                     | 84     |   |                                   |   | 14     |      |  |   | 108    |   |  |   | 62     |  
|Interest Expense                                           |  |                                     | (1,058 | ) |                                   |   | (1,611 | )    |  |   | (2,475 | ) |  |   | (3,180 | )
|Debt Issuance Cost Amortization                            |  |                                     | (97    | ) |                                   |   | (210   | )    |  |   | (225   | ) |  |   | (420   | )
|Equity Method Investment Income                            |  |                                     | 65     |   |                                   |   |       |      |  |   | 82     |   |  |   | 675    |  
|Loss on Early Extinguishment of Debt                       |  |                                     |       |   |                                   |   |       |      |  |   | (4,573 | ) |  |   |       |  
|Gain (Loss) on Derivatives                                 |  |                                     | (447   | ) |                                   |   |       |      |  |   | 1,204  |   |  |   |       |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Total Other Expense                                        |  |                                     | (1,453 | ) |                                   |   | (1,807 | )    |  |   | (5,879 | ) |  |   | (2,863 | )
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Loss Before Provision For Income Taxes                     |  |                                     | (1,360 | ) |                                   |   | (203   | )    |  |   | (2,568 | ) |  |   | (2,655 | )
|Provision For Income Taxes                                 |  |                                     | 372    |   |                                   |   | 1,064  |      |  |   | 1,154  |   |  |   | 1,411  |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Net Loss                                                   |  | $                                   | (1,732 | ) |                                   | $ | (1,267 | )    |  | $ | (3,722 | ) |  | $ | (4,066 | )
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Less: Net Loss Attributable to the Noncontrolling Interest |  |                                     | 16     |   |                                   |   |       |      |  |   | 16     |   |  |   |       |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Net Loss Attributable to BMP Sunstone Corporation          |  | $                                   | (1,716 | ) |                                   | $ | (1,267 | )    |  | $ | (3,706 | ) |  | $ | (4,066 | )
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Basic and Fully-Diluted Loss Per Share                     |  | $                                   | (0.04  | ) |                                   | $ | (0.03  | )    |  | $ | (0.09  | ) |  | $ | (0.11  | )
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Basic Weighted-average Shares Outstanding                  |  |                                     | 41,539 |   |                                   |   | 39,511 |      |  |   | 41,154 |   |  |   | 37,304 |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Diluted Weighted-average Shares Outstanding                |  |                                     | 50,699 |   |                                   |   | 40,850 |      |  |   | 46,875 |   |  |   | 38,719 |  
|                                                           |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  

See notes to condensed consolidated financial statements



4



---

##### Table of Contents

BMP SUNSTONE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)

($ in thousands)



|                                                           |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  
|---------------------------------------------------------- |  | --------------- |  | ------------- | -- | ------------------------ | - | ------- | ------------------- |  | - | ------------------ | - |  | ------------------------------------------------------------- | ------- | ---------------------- |  | - | -------------------- |  | - | --- | - |  | - | ------- | -
|                                                           |  | Numberof Shares |  | $.001ParValue |    | AdditionalPaid-inCapital |   |         | CommonStockWarrants |  |   | AccumulatedDeficit |   |  | AccumulatedOtherComprehensiveIncomeForeignCurrencyTranslation |         | NoncontrollingInterest |  |   | Stock-holdersEquity | 
|Balance as of December 31, 2008                            |  | 40,246,410      |  | $             | 40 |                          | $ | 160,864 |                     |  | $ | 9,049              |   |  | $                                                             | (31,042 | )                      |  | $ | 8,721                |  | $ |    |   |  | $ | 147,632 |  
|Stock-Based Compensation                                   |  |                |  |               |   |                          |   | 585     |                     |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | 585     |  
|Common Stock Issuance in connection with private placement |  | 1,118,124       |  |               | 1  |                          |   | 2,846   |                     |  |   | 731                |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | 3,578   |  
|Common Stock Warrants Issuance                             |  |                |  |               |   |                          |   | (838    | )                   |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | (838    | )
|Cost Incurred in Connection with Stock Issuance            |  |                |  |               |   |                          |   | (579    | )                   |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | (579    | )
|Common Stock Issuance in Connection with Debt Financing    |  | 135,875         |  |               |   |                          |   | 417     |                     |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | 417     |  
|Extinguishment of Derivative Liability                     |  |                |  |               |   |                          |   | 1,555   |                     |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | 1,555   |  
|Net Loss                                                   |  |                |  |               |   |                          |   |        |                     |  |   |                   |   |  |                                                               | (1,990  | )                      |  |   |                     |  |   |    |   |  |   | (1,990  | )
|Other Comprehensive Loss                                   |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  
|Foreign Currency Translation                               |  |                |  |               |   |                          |   |        |                     |  |   |                   |   |  |                                                               |        |                        |  |   | 245                  |  |   |    |   |  |   | 245     |  
|                                                           |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  
|Total Comprehensive Loss                                   |  |                |  |               |   |                          |   |        |                     |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | (1,745  | )
|                                                           |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  
|Balance as of March 31, 2009                               |  | 41,500,409      |  | $             | 41 |                          | $ | 164,850 |                     |  | $ | 9,780              |   |  | $                                                             | (33,032 | )                      |  | $ | 8,966                |  | $ |    |   |  | $ | 150,605 |  
|                                                           |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  
|Stock-Based Compensation                                   |  |                |  |               |   |                          |   | 599     |                     |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | 599     |  
|Common Stock Warrants Exercised                            |  | 58,496          |  |               | 1  |                          |   | 197     |                     |  |   | (130               | ) |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | 68      |  
|Common Stock Warrants Expired                              |  |                |  |               |   |                          |   | 1,029   |                     |  |   | (1,029             | ) |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   |        |  
|Extinguishment of Derivative Liability                     |  |                |  |               |   |                          |   | 1,342   |                     |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | 1,342   |  
|Noncontrolling Interest                                    |  |                 |  |               |    |                          |   | (439    | )                   |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   | 439 |   |  |   |        |  
|Net Loss                                                   |  |                |  |               |   |                          |   |        |                     |  |   |                   |   |  |                                                               | (1,716  | )                      |  |   |                     |  |   | (16 | ) |  |   | (1,732  | )
|Other Comprehensive Loss                                   |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  
|Foreign Currency Translation                               |  |                |  |               |   |                          |   |        |                     |  |   |                   |   |  |                                                               |        |                        |  |   | 348                  |  |   |    |   |  |   | 348     |  
|                                                           |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  
|Total Comprehensive Loss                                   |  |                |  |               |   |                          |   |        |                     |  |   |                   |   |  |                                                               |        |                        |  |   |                     |  |   |    |   |  |   | (1,384  | )
|                                                           |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  
|Balance as of June 30, 2009                                |  | 41,558,905      |  | $             | 42 |                          | $ | 167,578 |                     |  | $ | 8,621              |   |  | $                                                             | (34,748 | )                      |  | $ | 9,314                |  | $ | 423 |   |  | $ | 151,230 |  
|                                                           |  |                 |  |               |    |                          |   |         |                     |  |   |                    |   |  |                                                               |         |                        |  |   |                      |  |   |     |   |  |   |         |  

See notes to condensed consolidated financial statements



5



---

##### Table of Contents

BMP SUNSTONE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

($ in thousands)



|                                                                                |  |                                  |         |   |      |   |         |  
|------------------------------------------------------------------------------- |  | -------------------------------- | ------- | - | ---- | - | ------- | -
|                                                                                |  | For the six months ended June 30 |        
|                                                                                |  | 2009                             |         |   | 2008 |  
|Cash Flows from Operating Activities:                                           |  |                                  |         |   |      |   |         |  
|Net Loss                                                                        |  | $                                | (3,706  | ) |      | $ | (4,066  | )
|Adjustments to Reconcile Net Loss to Net Cash Provided in Operating Activities: |  |                                  |         |   |      |   |         |  
|Bad Debt Expense                                                                |  |                                  |        |   |      |   | 4       |  
|Depreciation and Amortization of Property and Equipment                         |  |                                  | 1,153   |   |      |   | 809     |  
|Amortization of Intangible Assets and Inventory at Fair Value                   |  |                                  | 1,772   |   |      |   | 2,095   |  
|Amortization of Debt Discount and Deferred Debt Issuance Costs                  |  |                                  | 630     |   |      |   | 1,954   |  
|Stock-Based Compensation                                                        |  |                                  | 1,184   |   |      |   | 1,180   |  
|Gain on Fair Value of Derivatives                                               |  |                                  | (1,204  | ) |      |   |        |  
|Loss on Early Extinguishment of Debt                                            |  |                                  | 4,573   |   |      |   |        |  
|Equity Method Investment Income                                                 |  |                                  | (82     | ) |      |   | (675    | )
|Loss on Disposal of Asset                                                       |  |                                  | 79      |   |      |   | 2       |  
|Non Controlling Interest                                                        |  |                                  | (16     | ) |      |   |        |  
|Decrease in Deferred Taxes                                                      |  |                                  | (223    | ) |      |   | (372    | )
|Increase in Accounts Receivable                                                 |  |                                  | (6,873  | ) |      |   | (2,188  | )
|Decrease in Notes Receivable                                                    |  |                                  | 2,914   |   |      |   |        |  
|Decrease (Increase) in Inventory                                                |  |                                  | 804     |   |      |   | (4,033  | )
|Increase in Other Receivables                                                   |  |                                  | (185    | ) |      |   | (2,677  | )
|Increase in Value Added Tax Receivable                                          |  |                                  | (219    | ) |      |   | (554    | )
|Decrease (Increase) in Prepaid Expenses and Other Current Assets                |  |                                  | 305     |   |      |   | (1,671  | )
|(Decrease) Increase in Accounts Payable                                         |  |                                  | (2,195  | ) |      |   | 5,258   |  
|Decrease in Due to Related Parties                                              |  |                                  | (1,132  | ) |      |   | (1,299  | )
|Decrease in Deferred Revenue                                                    |  |                                  |        |   |      |   | (1,363  | )
|Increase in Accrued Expenses                                                    |  |                                  | 1,025   |   |      |   | 1,314   |  
|                                                                                |  |                                  |         |   |      |   |         |  
|Net Cash Used in Operating Activities                                           |  |                                  | (1,396  | ) |      |   | (6,282  | )
|                                                                                |  |                                  |         |   |      |   |         |  
|Cash Flows from Investing Activities:                                           |  |                                  |         |   |      |   |         |  
|Acquisition of Property and Equipment                                           |  |                                  | (1,861  | ) |      |   | (1,956  | )
|Payment for Land Use Rights                                                     |  |                                  | (901    | ) |      |   |        |  
|Cash Received in Acquisition of Sunstone China                                  |  |                                  |        |   |      |   | 2,132   |  
|Investment in Alliance BMP                                                      |  |                                  |        |   |      |   | (12,319 | )
|Deposit on Rongheng                                                             |  |                                  |        |   |      |   | (1,565  | )
|Note Receivable with Rongheng                                                   |  |                                  |        |   |      |   | 212     |  
|Investment in Shengda                                                           |  |                                  | (818    | ) |      |   |        |  
|                                                                                |  |                                  |         |   |      |   |         |  
|Net Cash Used In Investing Activities                                           |  |                                  | (3,580  | ) |      |   | (13,496 | )
|                                                                                |  |                                  |         |   |      |   |         |  
|Cash Flows from Financing Activities:                                           |  |                                  |         |   |      |   |         |  
|Net Proceeds from Common Stock Issuance                                         |  |                                  | 2,999   |   |      |   |        |  
|Net Proceeds from Long Term Debt Issuance                                       |  |                                  | 12,031  |   |      |   |        |  
|Retirement of Long Term Debt                                                    |  |                                  | (11,350 | ) |      |   |        |  
|Increase in Restricted Cash                                                     |  |                                  | (413    | ) |      |   |        |  
|Net Proceeds from Exercise of Warrants and Options                              |  |                                  | 68      |   |      |   | 541     |  
|Payments on Note Payable                                                        |  |                                  |        |   |      |   | 475     |  
|Net Payments on bank borrowings                                                 |  |                                  | (5,407  | ) |      |   |        |  
|                                                                                |  |                                  |         |   |      |   |         |  
|Net Cash (Used in) Provided by Financing Activities                             |  |                                  | (2,072  | ) |      |   | 1,016   |  
|                                                                                |  |                                  |         |   |      |   |         |  
|Effect of exchange rate changes on cash                                         |  |                                  | 209     |   |      |   | 627     |  
|                                                                                |  |                                  |         |   |      |   |         |  
|Net Decrease in Cash and Equivalents                                            |  |                                  | (6,839  | ) |      |   | (18,135 | )
|Cash and Equivalents, Beginning                                                 |  |                                  | 15,740  |   |      |   | 22,837  |  
|                                                                                |  |                                  |         |   |      |   |         |  
|Cash and Equivalents, Ending                                                    |  | $                                | 8,901   |   |      | $ | 4,702   |  
|                                                                                |  |                                  |         |   |      |   |         |  
|Supplemental Disclosure of Cash Flow Information:                               |  |                                  |         |   |      |   |         |  
|Cash Paid During the Years for:                                                 |  |                                  |         |   |      |   |         |  
|Income Taxes                                                                    |  | $                                | 3,191   |   |      | $ | 1,800   |  
|Interest                                                                        |  | $                                | 2,307   |   |      | $ | 1,463   |  
|                                                                               
|Non-Cash Investing and Financing Activities:                                    | 
|Issuance of January Exchange Notes for 10.0% Notes                              |  | $                                | 10,650  |   |      |   |        |  
|Issuance of March Exchange Notes for 10.0% Notes                                |  | $                                | 1,000   |   |      |   |        |  



6



---

##### Table of Contents

BMP SUNSTONE CORPORATION AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation:

The accompanying unaudited condensed consolidated financial statements as of June 30, 2009 and for the three and six months ended June 30, 2009
and 2008 of BMP Sunstone Corporation (formerly Beijing Med-Pharm Corporation) and subsidiaries (collectively, the Company, we or our) include the accounts of BMP Sunstone Corporation (the Parent) and
its direct and indirect owned subsidiaries, Beijing Medpharm Co. Ltd. (BMP China), Beijing Wanwei Pharmaceutical Co., Ltd. (Wanwei), Sunstone China Limited (Sunstone China), the 100% owner of Sunstone (Tangshan)
Pharmaceutical Co., Ltd (Sunstone) and Shanghai Rongheng Pharmaceutical, Ltd (Rongheng) and should be read in conjunction with the audited consolidated financial statements and accompanying footnotes of the Company as of
December 31, 2008 and 2007, and for each of the three years for the period ended December 31, 2008, included in the Companys Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange
Commission (the SEC) on March 17, 2009. The condensed consolidated balance sheet of the Company at December 31, 2008, presented with in this report on Form 10-Q has been derived from audited financial statements at that date. In the
opinion of management, the accompanying unaudited consolidated financial statements contain all material adjustments, consisting principally of normal recurring adjustments, necessary for a fair presentation of the Companys interim results.
Certain information and footnote disclosures required for complete financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant
to applicable rules and regulations. The operating results for the interim periods are not necessarily indicative of the results to be expected for the full year.

Earnings Per Share: The Company calculates basic earnings per share based on the weighted-average number of outstanding common shares. The Company calculates diluted earnings per share based on the
weighted-average number of outstanding common shares plus the effect of dilutive stock options and warrants. Common stock equivalents have been excluded from the diluted per share calculations as of June 30, 2009 and 2008, as the Company has
incurred a net loss during the three month and six month period then ended, and their inclusion would have been anti-dilutive.

Recent
Accounting Pronouncements: On January 1, 2008, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 157,Fair Value Measurements, or SFAS No. 157, as it relates to financial assets and
financial liabilities. In February 2008, the Financial Accounting Standards Board (FASB) issued FASB Staff Position (FSP) No. FAS 157-2,Effective Date of FASB Statement No. 157, or FSP No. FAS
157-2, which delayed the effective date of SFAS No. 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on at least an annual basis, until
January 1, 2009 for calendar year-end entities. SFAS No. 157 and FSP No. FAS 157-2 are effective for financial statements issued for fiscal years beginning after November 15, 2007.

SFAS No. 157 defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value
measurements. The provisions of this standard apply to other accounting pronouncements that require or permit fair value measurements and are to be applied prospectively with limited exceptions. The adoption of SFAS No. 157, as it relates to
financial assets and financial liabilities, had no significant impact on the Companys financial statements. Management has adopted SFAS No. 157 as of the effective date, as it relates to nonfinancial assets and nonfinancial liabilities
and there was no significant impact on the Companys financial statements. SFAS No. 157 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are
described below:

Level 1Unadjusted quoted prices in active markets that are accessible at the measurement date for identical,
unrestricted assets or liabilities.

Level 2Inputs other than quoted prices included within Level 1 that are observable for the asset
or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices
that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3Inputs that are both significant to the fair value measurement and unobservable.



7



---

##### Table of Contents

In October 2008, the FASB issued FSP No. FAS 157-3,Determining the Fair Value of a
Financial Asset When the Market for That Asset Is Not Active, or FSP No. FAS 157-3. This FSP clarifies the application of SFAS No. 157 in a market that is not active and provides an example to illustrate key considerations in
determining the fair value of a financial asset when the market for that financial asset is not active. FSP No. FAS 157-3 is effective upon issuance, including prior periods for which financial statements have not been issued. The Company
adopted FSP No. FAS 157-3 for the period ended December 31, 2008 and the adoption did not have any significant impact on its consolidated balance sheets, statements of operations, or disclosures.

The fair value of cash equivalents and restricted cash was $10.5 million at June 30, 2009. These financial instruments are classified in Level
1 of the fair value hierarchy described above.

In December 2007, the Financial Accounting Standards Board issued Statement 141
(revised 2007), Business Combinations (Statement 141R), to change how an entity accounts for the acquisition of a business. Statement 141R replaces existing Statement 141 in its entirety for business combinations. Statement 141R carries forward the
existing requirements to account for all business combinations using the acquisition method (formerly called the purchase method). In general, Statement 141R requires acquisition-date fair value measurement of identifiable assets acquired,
liabilities assumed, and noncontrolling interests in the acquiree. Statement 141R eliminates the current cost-based purchase method under Statement 141.

The new measurement requirements result in the recognition of the full amount of acquisition-date goodwill, which includes amounts attributable to noncontrolling interests. The acquirer recognizes in income any gain
or loss on the remeasurement to acquisition-date fair value of consideration transferred or of previously acquired equity interests in the acquiree. Neither the direct costs incurred to effect a business combination nor the costs the acquirer
expects to incur under a plan to restructure an acquired business may be included as part of the business combination accounting. As a result, those costs are charged to expense when incurred, except for debt or equity issuance costs, which are
accounted for in accordance with other generally accepted accounting principles.

Statement 141R also changes the accounting for in-process
research and development, and restructuring costs. In addition, after Statement 141R is adopted, changes in uncertain tax positions or valuation allowances for deferred tax assets acquired in a business combination are recognized as adjustments to
income tax expense or contributed capital, as appropriate, even if the deferred tax asset or tax position was initially acquired prior to the effective date of Statement 141R.

The Company adopted Statement 141R as of the required effective date of January 1, 2009. The adoption of Statement 141R did not have any significant
impact on the Companys consolidated balance sheets, statement of operations or disclosures.

In April 2008, the FASB issued FSP
No. FAS 142-3,Determination of Useful Life of Intangible Assets, or FSP No. FAS 142-3. FSP No. FAS 142-3 amends the factors that should be considered in developing the renewal or extension assumptions used to determine the
useful life of a recognized intangible asset under SFAS No. 142,Goodwill and Other Intangible Assets . FSP No. FAS 142-3 also requires expanded disclosure related to the determination of intangible asset useful lives. FSP No. FAS
142-3 is effective for fiscal years beginning after December 15, 2008. The Company has adopted FSP No. FAS 142-3 as of the required effective date of January 1, 2009 and the adoption did not have any significant impact on its
consolidated balance sheets, statements of operations, or disclosures.

In June 2008, the FASB issued EITF Issue No. 07-5,Determining Whether an Instrument (or Embedded Feature) is Indexed to an Entitys Own Stock , or EITF Issue No. 07-5. This EITF is effective for financial statements issued for fiscal years beginning after December 15, 2008, and
interim periods within those fiscal years. Early application is not permitted. Paragraph 11(a) of SFAS No. 133,Accounting for Derivatives and Hedging Activities, or SFAS No. 133, specifies that a contract that would otherwise meet
the definition of a derivative but is both (a) indexed to the Companys own stock and (b) classified in stockholders equity in the statement of financial position would not be considered a derivative financial instrument. EITF
Issue No. 07-5 provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuers own stock and thus able to qualify for the SFAS No. 133 paragraph 11(a) scope
exception. The Company has adopted this EITF as of January 1, 2009 in its evaluation of its derivatives.



8



---

##### Table of Contents

In March 2008, the Financial Accounting Standards Board issued Statement 161, Disclosures about
Derivative Instruments and Hedging Activities, to expand the disclosure framework in FASB Statement 133, Accounting for Derivative Instruments and Hedging Activities. The new Statement requires companies with derivative instruments to disclose
information about how and why the company used derivative instruments; how the company accounts for derivative instruments and related hedged items under Statement 133; and how derivative instruments and related hedged items affect the
companys financial position, financial performance, and cash flows. The expanded disclosure guidance also requires a company to provide information about its strategies and objectives for using derivative instrument; disclose
credit-risk-related contingent features in derivative agreements and information about counterparty credit risk; and present the fair value of derivative instruments and related gains or losses in a tabular format. The Company adopted Statement 161
as of the required effective date of January 1, 2009 and applied its provisions prospectively by providing the additional disclosures in its financial statements.

In June 2008, the FASB issued EITF Issue No. 08-4,Transition Guidance for Conforming Changes to Issue No. 98-5, or EITF Issue No. 08-4. The objective of this EITF is to provide transition
guidance for conforming changes made to EITF Issue No. 98-5,Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios, or EITF Issue No. 98-5, that result from EITF Issue
No. 00-27,Application of Issue No. 98-5 to Certain Convertible Instruments, or EITF Issue No. 00-27, and SFAS No. 150,Accounting for Certain Financial Instruments with Characteristics of both Liabilities and
Equity, or SFAS No. 150. This Issue is effective for financial statements issued for fiscal years ending after December 15, 2008. Early application is permitted. The Company adopted EITF Issue No. 08-4 as of the required effective
date of January 1, 2009 and it did not have a material impact on its consolidated financial position and results of operation.

In
November 2008, the FASB issued EITF Issue No. 08-8, Accounting for an Instrument (or an Embedded Feature) with a Settlement Amount That Is Based on the Stock of an Entitys Consolidated Subsidiary, or EITF Issue No. 08-8.
EITF Issue No. 08-8 clarifies whether a financial instrument for which the payoff to the counterparty is based, in whole or in part, on the stock of an entitys consolidated subsidiary is indexed to the reporting entitys own stock.
EITF Issue No. 08-8 is effective for fiscal years beginning on or after December 15, 2008, and interim periods within those fiscal years. The Company has adopted EITF Issue No. 08-8 and it did not have a material impact on its
consolidated financial position and results of operations.

In April 2009, the FASB issued FSP FAS 107-1 and Accounting Principles Board
(APB) Opinion No. 28-1, Interim Disclosures about Fair Value of Financial Instruments (FSP FAS 107-1 and APB 28-1). FSP FAS 107-1 and APB 28-1 amended SFAS No. 107, Disclosures about Fair Value of
Financial Instruments, and APB Opinion No. 28, Interim Financial Reporting, to require disclosures about the fair value of financial instruments in interim as well as in annual financial statements. The adoption of this
standard has resulted in additional disclosures only in our interim financial statements, and therefore did not impact our financial position, results of operations or cash flows. The Company has adopted FSP FAS 107-1 and APB 28-1 as of the required
effective date of June 15, 2009. See Note 4 for discussion of fair value measurements of our derivative instruments.

In May 2009, the
Financial Accounting Standards Board issued Statement 165, Subsequent Events, to incorporate the accounting and disclosure requirements for subsequent events into U.S. generally accepted accounting principles. Statement 165 introduces new
terminology, defines a date through which management must evaluate subsequent events, and lists the circumstances under which an entity must recognize and disclose events or transactions occurring after the balance-sheet date. The Company adopted
Statement 165 as of June 30, 2009, which was the required effective date.

The Company evaluated its June 30, 2009 financial
statements for subsequent events through August 10, 2009, the date the financial statements were issued. Other than the agreement described in Note 10, the Company is not aware of any subsequent events which would require recognition or
disclosure in the financial statements.

In June 2009, the FASB issued SFAS No. 168, The FASB Accounting Standards Codification
and the Hierarchy of Generally Accepted Accounting Principles  a replacement of FASB Statement No. 162 (SFAS 168). SFAS 168 replaces SFAS No. 162, The Hierarchy of Generally Accepted Accounting Principles
and establishes the FASB Accounting Standard Codification  (Codification) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial
statements in conformity with generally accepted accounting principles in the United States. All guidance contained in the Codification carries an equal level of authority. On the effective date of SFAS 168, the Codification will supersede all
then-existing non-SEC accounting and reporting standards. All other nongrandfathered non-SEC accounting literature



9



---

##### Table of Contents

not included in the Codification will become nonauthoritative. SFAS 168 is effective for financial statements issued for interim and annual periods ending
after September 15, 2009. We have evaluated this new statement, and have determined that it will not have a significant impact on the determination or reporting of our financial results.

2. Acquisitions:

Acquisition of Zhangjiakou Shengda
Pharmaceutical Co., Ltd

On December 19, 2008, Sunstone entered into an Equity Transfer Agreement with Beijing Penn
Pharmaceutical Sci-Tech Development Co., Ltd. (Beijing Penn) to purchase 50% of the outstanding equity interests of Zhangjiakou Shengda Pharmaceutical Co., Ltd. (Shengda) for RMB 20.0 million (or $2,920,000 as of
February 16, 2009) in cash. On February 16, 2009 we received the business license of Shengda and closed on the acquisition. Shengda has changed its name to Sunstone Shengda (Zhangjiakou) Pharmaceutical Co., Ltd.

The purchase price is payable in installments:



| |  |  | RMB 6 million (or $875,000 as of December 31, 2008) was payable within 15 business days following the signing of the Equity Transfer Agreement and was paid as
of December 31, 2008;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | RMB 14 million (or $2,045,000 as of June 30, 2009) is payable in five equal installments on the second, fourth, sixth, eighth and tenth month anniversary
following the closing of the transactions contemplated by the Equity Transfer Agreement.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pursuant to the Equity Transfer
Agreement, the Company purchased 50% of the outstanding equity interests of Shengda from Beijing Penn. Shengda is a Sino-foreign joint venture corporation with a contract period of 30 years. Following the transactions as completed by the Equity
Transfer Agreement, the Company is one of three shareholders of Shengda. The investment in Shengda was accounted for in accordance with Accounting Principles Board Opinion 18 under the equity method of accounting. Our total investment in Shengda was
$3,003,000 as of June 30, 2009, of which we had paid $1,696,000. There were no acquisition costs incurred during the three or six months ended June 30, 2009.

The following table summarizes the allocation of the purchase price for the proportionate share of Shengdas net assets acquired at fair value.



|                                                                                  |  |                                        |       |                  |      
|--------------------------------------------------------------------------------- |  | -------------------------------------- | ----- | ---------------- | -----
|                                                                                  |  |                                        |       | ($ in thousands)
|Purchase Price                                                                    |  | $                                      | 2,920
|Less:                                                                             |  | Fair value of identifiable assets      |       |                  |      
|                                                                                  |  | Cash                                   |       |                  | 398  
|                                                                                  |  | Accounts receivable                    |       |                  | 68   
|                                                                                  |  | Other receivable                       |       |                  | 84   
|                                                                                  |  | Prepaid expenses and other assets      |       |                  | 38   
|                                                                                  |  | Inventory                              |       |                  | 512  
|                                                                                  |  | Fixed assets                           |       |                  | 743  
|                                                                                  |  |                                        |       |                  |      
|                                                                                  |  |                                        |       |                  | 1,843
|Plus:                                                                             |  | Fair value of liabilities assumed      |       |                  |      
|                                                                                  |  | Accounts payable                       |       |                  | 275  
|                                                                                  |  | Accrued liabilities and other payables |       |                  | 432  
|                                                                                  |  |                                        |       |                  |      
|                                                                                  |  |                                        |       |                  | 707  
|                                                                                  |  |                                        |       |                  |      
|Excess of cost over fair value of net assets acquired excluding intangible assets |  | $                                      | 1,784
|                                                                                  |  |                                        |       |                  |      



10



---

##### Table of Contents

The following is the relative fair value of the identifiable intangible assets as of the date of
acquisition.



|                                    |  |                                    |                      |               |                         |  |               |    |  |   |      
|----------------------------------- |  | ---------------------------------- | -------------------- | ------------- | ----------------------- |  | ------------- | -- |  | - | -----
|                                    |  | Weighted AverageAmortizationPeriod |                      | June 30, 2009
|                                    |  |                                    | Gross CarryingAmount |               | AccumulatedAmortization |  | Net BookValue
|Intangible assets                   |  |                                    |                      |               |                         |  |               |    |  |   |      
|Completed Technology                |  | 11.8 Years                         |                      |               | 983                     |  |               | 30 |  |   | 953  
|Trademark                           |  | 11.8 Years                         |                      |               | 357                     |  |               | 10 |  |   | 347  
|In Process Research and Development |  | 16.0 Years                         |                      |               | 209                     |  |               | 4  |  |   | 205  
|Customer Relationship               |  | 5 Years                            |                      |               | 192                     |  |               | 40 |  |   | 152  
|GMP License                         |  | 2 Years                            |                      |               | 43                      |  |               | 7  |  |   | 36   
|                                    |  |                                    |                      |               |                         |  |               |    |  |   |      
|Intangible Assets                   |  |                                    |                      | $             | 1,784                   |  | $             | 91 |  | $ | 1,693
|                                    |  |                                    |                      |               |                         |  |               |    |  |   |      

The intangible assets are being amortized over estimated useful lives as described above from the
date of the acquisition and recorded against our equity in earnings. The following table provides a reconciliation of our equity method investment income for the period February 16, 2009 through June 30, 2009. Prior to purchase accounting
adjustments Shengda generated net income of $474,000, or $237,000 for our 50% equity ownership. The total of amortization for the period was $155,000 which resulted in equity method investment income of $82,000.

Reconciliation of Equity Method Investment Income:



|                                                                                                    |  |                  |     |  
|--------------------------------------------------------------------------------------------------- |  | ---------------- | --- | -
|                                                                                                    |  | ($ in thousands) |    
|Equity in earnings of Shengda for the period                                                        |  |                  |     |  
|February 16 through June 30, 2009                                                                   |  | $                | 237 |  
|Less adjustments of excess fair value:                                                              |  |                  |     |  
|Inventory sold                                                                                      |  |                  | (61 | )
|Depreciation and amortization expense on buildings and intangible assets, including land use rights |  |                  | (94 | )
|                                                                                                    |  |                  |     |  
|Total equity method investment income                                                               |  | $                | 82  |  
|                                                                                                    |  |                  |     |  

Acquisition of Taiyangshi Fulai Tangshan Pharmaceutical Co., Ltd.

On April 12, 2009, Sunstone entered into a joint venture agreement with Tangshan Yangguang Fulai Business Consultants Co., Ltd. (Tangshan SunshineFly) to
establish Taiyangshi Fulai Tangshan Pharmaceutical Co., Ltd. (Sunstone Fulai), located in Yutian County, Tangshan. Sunstone Fulai is owned 70% by Sunstone and 30% by Tangshan SunshineFly. The joint venture agreement requires Sunstone to inject RMB
35 million (or $5.2 million as of April 15, 2009) and Tangshan SunshineFly to contribute technology with an estimated value of RMB 15 million (or $2.2 million as of April 15, 2009). On April 16, 2009, Sunstone Fulai received
the business license.

Sunstones capital contribution is payable in installments:



| |  |  | RMB 10 million (or $1,462,000 as of April 15, 2009) was paid April 15, 2009;
| | - |  | ----------------------------------------------------------------------------



| |  |  | RMB 10 million (or $1,461,000 as of July 21, 2009) was paid as of July 21, 2009;
| | - |  | --------------------------------------------------------------------------------



| |  |  | RMB 10 million (or $1,461,000 as of June 30, 2009) is payable December 15, 2009; and
| | - |  | ------------------------------------------------------------------------------------



| |  |  | RMB 5 million (or $730,000 as of June 30, 2009) is payable December 15, 2010.
| | - |  | -----------------------------------------------------------------------------



11



---

##### Table of Contents

In acquiring our 70 percent interest in Sunstone Fulai, Sunstone has agreed to inject RMB 35 million
of which RMB 10 million was injected as of June 30, 2009. Tangshan SunshineFly will contribute production technology at a later date once the manufacturing facility is completed. For financial reporting purposes, we have accounted for
Sunstone Fulai as a consolidated subsidiary from April 16, 2009 through June 30, 2009.

The noncontrolling interest of Tangshan
SunshineFly represents the fair value of 30 percent of Sunstones cash injection in April 2009 or RMB 3 million (or $439,000 as of April 16, 2009) adjusted for 30% of the net loss of Sunstone Fulai. For the period April 16, 2009
through June 30, 2009, Sunstone Fulai generated a loss of $52,000.



|                                                                                 |  |                  |     |  
|-------------------------------------------------------------------------------- |  | ---------------- | --- | -
|                                                                                 |  | ($ in thousands) |    
|Noncontrolling interest:                                                         |  |                  |     |  
|30% of Sunstones April 16 payment allocated to Tangshan SunshineFly             |  | $                | 439 |  
|Less: Loss in Sunstone Fulai for the period April 16, 2009 through June 30, 2009 |  |                  | (16 | )
|                                                                                 |  |                  |     |  
|Noncontrolling interest                                                          |  |                  | 423 |  
|                                                                                 |  |                  |     |  

Pro forma results have not been included as Sunstone Fulai manufacturing plant is currently being
constructed and is expected to be completed in 2010.

3. Segment Information:

The Company has three reportable segments; (i) the branded OTC sale reportable segment which includes the operations of Sunstone, (ii) the
Pharmaceutical Distribution reportable segment which includes the operations of Wanwei and Rongheng and (iii) the Licensed Products reportable segment which includes the operations of BMP China.

Branded OTC Segment (Sunstone)

The chief
operating decision maker for the Branded OTC segment is the President and Chief Operating Officer of the Company, whose function is to allocate resources to, and assess the performance of, Sunstone and Sunstone Fulai. This segment primarily
manufactures and sells branded products into the retail pharmacy supply chain. Sunstone operates in a high margin environment selling pediatric and womens health pharmaceutical and nutritional products. Sunstones revenues are seasonal
with the majority of sales related to cough, cold and flu products.

Pharmaceutical Distribution Segment (Wanwei and Rongheng)

The chief operating decision makers for the Pharmaceutical Distribution segment are the General Managers of Wanwei and Rongheng, whose function is to
allocate resources to, and assess the performance of, their respective business. This segment services both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel. The warehousing and distribution of
pharmaceutical drugs, which are purchased from different suppliers, is the primary business activity of Wanwei and Rongheng. Pharmaceutical Distribution operates in a high volume and low margin environment.

Wanwei and Rongheng distribute prescription pharmaceuticals, over-the-counter healthcare products and home healthcare supplies and equipment to a variety
of healthcare providers.

Licensed Products Segment (BMP China)

The chief operating decision maker for the sales and marketing segment is the Corporate Vice President and General Manager of BMP China, whose function is to allocate resources to, and assess the performance of, BMP
China. This segment markets exclusively licensed prescription drugs nationwide to healthcare providers of prescription drugs.



12



---

##### Table of Contents

The following tables present reportable segment information for the periods indicated:



|                                 |  |                                                    |        |   |                                                  |   |        |      |  |   |        |   |  |   |        |  
|-------------------------------- |  | -------------------------------------------------- | ------ | - | ------------------------------------------------ | - | ------ | ---- |  | - | ------ | - |  | - | ------ | -
|                                 |  | RevenueThree months ended June 30,                 |        |   | RevenueSix months ended June 30,                 |  
|                                 |  | 2009                                               |        |   | 2008                                             |   |        | 2009 |  |   | 2008   |  
|                                 |  | ($ in thousands)                                   |        |   | ($ in thousands)                                 |  
|Branded OTC (i)                  |  | $                                                  | 16,810 |   |                                                  | $ | 19,612 |      |  | $ | 41,337 |   |  | $ | 29,069 |  
|Pharmaceutical Distribution (ii) |  |                                                    | 15,758 |   |                                                  |   | 9,966  |      |  |   | 30,516 |   |  |   | 18,598 |  
|Licensed Products                |  |                                                    | 1,292  |   |                                                  |   | 424    |      |  |   | 2,320  |   |  |   | 743    |  
|Eliminations                     |  |                                                    | (1,377 | ) |                                                  |   | (364   | )    |  |   | (2,427 | ) |  |   | (683   | )
|                                 |  |                                                    |        |   |                                                  |   |        |      |  |   |        |   |  |   |        |  
|Total Revenue                    |  | $                                                  | 32,483 |   |                                                  | $ | 29,638 |      |  | $ | 71,746 |   |  | $ | 47,727 |  
|                                 |  |                                                    |        |   |                                                  |   |        |      |  |   |        |   |  |   |        |  
|                                 |  |                                                   
|                                 |  | Operating Income (Loss)Three months ended June 30, |        |   | Operating Income (Loss)Six months ended June 30, |  
|                                 |  | 2009                                               |        |   | 2008                                             |   |        | 2009 |  |   | 2008   |  
|                                 |  | ($ in thousands)                                   |        |   | ($ in thousands)                                 |  
|Branded OTC (i)                  |  | $                                                  | 2,435  |   |                                                  | $ | 4,053  |      |  | $ | 7,680  |   |  | $ | 5,336  |  
|Pharmaceutical Distribution (ii) |  |                                                    | 33     |   |                                                  |   | 2      |      |  |   | (89    | ) |  |   | (388   | )
|Licensed Products                |  |                                                    | (18    | ) |                                                  |   | (621   | )    |  |   | 50     |   |  |   | (1,316 | )
|Corporate                        |  |                                                    | (2,091 | ) |                                                  |   | (1,318 | )    |  |   | (4,103 | ) |  |   | (2,724 | )
|Eliminations                     |  |                                                    | (266   | ) |                                                  |   | (512   | )    |  |   | (227   | ) |  |   | (700   | )
|                                 |  |                                                    |        |   |                                                  |   |        |      |  |   |        |   |  |   |        |  
|Total Operating Profit           |  | $                                                  | 93     |   |                                                  | $ | 1,604  |      |  | $ | 3,311  |   |  | $ | 208    |  
|                                 |  |                                                    |        |   |                                                  |   |        |      |  |   |        |   |  |   |        |  



|(i) | Sunstones Revenues and operating income for the six months ended June 30, 2008 is for the period February 18, 2008 through June 30, 2008. Sunstone Fulai is
included for the period April 16, 2009 through June 30, 2009.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(ii) | Revenues and operating income includes Wanwei for the six months ended June 30, 2009 and 2008, and Rongheng for the six months ended June 30, 2009.
|---- | ---------------------------------------------------------------------------------------------------------------------------------------------------

4. Long Term Debt

On
January 20, 2009, BMP Sunstone Corporation (the Parent) completed an exchange (the Exchange) of $10,650,000 in principal amount of its 10.0% senior secured promissory notes (the 10.0% Notes) for $10,650,000
in principal amount of its 12.5% secured convertible notes (the January Exchange Notes), pursuant to note exchange agreements (the Note Exchange Agreements) by and between the Company and certain holders of the 10.0% Notes
(the Note holders). Following the Exchange, $12,350,000 in principal amount of 10.0% Notes remained outstanding.

Pursuant to
the Note Exchange Agreements, the Company issued the January Exchange Notes in the aggregate principal amount of $10,650,000 to the Note holders. The January Exchange Notes bear interest at a rate of 12.5% per annum, payable quarterly in
arrears beginning on April 1, 2009. The January Exchange Notes have a maturity date of July 1, 2011. The accrued but unpaid interest on the 10.0% Notes prior to the Exchange was paid to the Note holders participating in the Exchange on
April 1, 2009.

Based upon the original terms of the January Exchange Notes, a Note holder may convert its January Exchange Note into
fully paid and non-assessable shares of common stock, par value $0.001 per share (the Common Shares), of the Company from time to time at a conversion price, subject to certain adjustments, equal to $5.00. If the Company issues Common
Shares in one or more offerings to investors on or prior to September 15, 2009 (other than any offerings following the issuance of Common Shares in one or more offerings to investors resulting in the receipt of proceeds (net of all commissions)
by the Company in an aggregate amount of at least $16,000,000), the conversion price will equal the lesser of (i) $5.00 or (ii) 115% of the lowest price per Common Share for which the Company sells Common Shares in any offering.

Notwithstanding the foregoing, pursuant to certain amendments to the January Exchange Notes, dated as of January 29, 2009, if the
conversion price of the January Exchange Notes would result, upon conversion of all such notes, in the issuance of Common Shares in amount equal to or greater than 8,049,282 Common Shares (which was equal to 20.00% of 40,246,410, which was the



13



---

##### Table of Contents

number of outstanding Common Shares on the date thereof), the conversion price shall be increased to $1.33 (which is equal to the principal amount of the
January Exchange Notes of $10,650,000 divided by 8,049,282 increased to the nearest whole cent), which would result, upon conversion of all of the January Exchange Notes, in the issuance of Common Shares in an aggregate amount less than 20.00% of
the outstanding Common Shares on the date thereof. The January Exchange Notes were further amended by that certain January Exchange Note Second Amendment (as defined below) and that certain January Exchange Note Third Amendment (as defined below).

At the date of issuance of the January Exchange Notes , the Company was subject to the terms of an embedded derivative instrument due to
the fact that the related contract was not indexed to its own stock, as specified by EITF No. 07-5,Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entitys Own Stock.

The Company determined that the convertible note instrument contained an embedded derivative. The fair value of the embedded derivative was determined to
be $3,262,000, and was recorded as a derivative liability at inception. That amount is being accreted through charges to the consolidated statements of operations using the effective interest method over the period of the January Exchange Notes. At
March 13, 2009, the date of the January Exchange Note amendment, the fair value of the derivative was $1,555,000. The decrease in the fair value of the derivative between January 20, 2009 and March 13, 2009 was recorded in the
consolidated statements of operations as a gain on derivative during the quarter ended March 31, 2009.

As of March 13, 2009, the
January Exchange Notes were amended to remove the aforementioned down-round clause relating to offerings to investors on or prior to September 15, 2009, so that the conversion price, subject to certain adjustments, became fixed at
$3.00.

The Company amended the January Exchange Notes (the January Exchange Notes Second Amendment) such that the definition
of certain terms and the mechanics of conversion of the January Exchange Notes parallel those in the March Exchange Notes and to restrict the issuance of Company securities to officers and directors of the Company below an effective price of $3.00
per common share. A Note holder may convert its January Exchange Note into fully paid and non-assessable shares of common stock, par value $0.001 per share (the Common Shares), of the Company from time to time at a conversion price,
subject to certain adjustments, equal to $3.00. The Company further amended the January Exchange Notes on May 14, 2009 (the January Exchange Notes Third Amendment) such that the conversion price was set at an amount equal to $3.00
per share of common stock and to add a covenant stating that the Company shall not issue equity, convertible debt or securities convertible into equity at an amount equal to or less than $2.75 per share of common stock (with such $2.75 amount to
include the fair value of any option, warrant or similar right offered by the Company and to be adjusted in the manner identical to the adjustment of the conversion price as provided in amended note agreement of the January Exchange Notes) until
December 31, 2009. The January Exchange Notes Third Amendment was effective as of March 13, 2009.

As of March 13, 2009, the
derivative liability was extinguished and recorded as additional paid-in capital, in accordance with EITF Issue No. 06-7,Issuers Accounting for a Previously Bifurcated Conversion Option in a Convertible Debt Instrument When the
Conversion Option No Longer Meets the Bifurcation Criteria in FASB Statement No. 133.

The derivative was not intended to hedge
any specific risk exposures, such as fluctuating interest rates, exchange rates, commodity prices, etc. Therefore, the derivative constituted neither a cash flow hedge, nor a fair value hedge. The volume of derivative activity relates solely to the
embedded derivative instrument itself, and changes in fair value thereon.



14



---

##### Table of Contents

Tabular disclosure of the fair value of the derivative instrument in the consolidated balance sheets, and
the effect of the derivative instrument on the consolidated balance sheets follows:



|                                                                 |  |                                          |  |                 
|---------------------------------------------------------------- |  | ---------------------------------------- |  | ----------------
|                                                                 |  | As of June 30, 2009Liability Derivatives
|                                                                 |  | Balance Sheet Location                   |  | Fair Value      
|                                                                 |  |                                          |  | ($ in thousands)
|Derivatives designated as hedging instruments under FAS 133:     |  |                                          |  |                 
|None                                                             |  |                                          |  |                 
|Derivatives not designated as hedging instruments under FAS 133: |  |                                          |  |                 
|Embedded Derivative                                              |  | None                                     |  |                 
|                                                                 |  |                                          |  |                 
|Total derivatives                                                |  |                                          |  |                 
|                                                                 |  |                                          |  |                 

The effect of the derivative instrument on the consolidated statements of operations for the six
months ended June 30, 2009 follows:



|                                                                 |  |                                                       |  |                                                                                         |      
|---------------------------------------------------------------- |  | ----------------------------------------------------- |  | --------------------------------------------------------------------------------------- | -----
|                                                                 |  | Location of Gain (Loss) Recognized inIncome Statement |  | Amount of Gain (Loss)Recognized in IncomeStatement for
theSix Months Ended June 30,2009
|                                                                 |  |                                                       |  | ($ in thousands)                                                                       
|Derivatives not designated as hedging instruments under FAS 133: |  |                                                       |  |                                                                                         |      
|Embedded Derivative                                              |  | Other Income (Expense)                                |  | $                                                                                       | 1,707
|                                                                 |  |                                                       |  |                                                                                         |      
|Total                                                            |  |                                                       |  | $                                                                                       | 1,707
|                                                                 |  |                                                       |  |                                                                                         |      

The fair value of the derivative liability was determined using the Black Scholes Option Pricing
method. The valuation methodology uses a combination of observable (Level 2) and unobservable (Level 3) inputs in calculating fair value. As required by FAS 157, assets are classified in their entirety based on the lowest level of input that is
significant to the fair value measurement.

The table below sets forth a summary of changes in the fair value of the Companys level 3
derivative for the six months ended June 30, 2009.



|                                                                     |  |                  |        |  
|-------------------------------------------------------------------- |  | ---------------- | ------ | -
|                                                                     |  | ($ in thousands) |       
|Balance as of December 31, 2008                                      |  | $                | 0      |  
|Record Derivative Liability on Conversion Option at January 20, 2009 |  |                  | 3,262  |  
|Change in Fair Value of Derivative Liability                         |  |                  | (1,707 | )
|Extinguishment of Derivative Liability                               |  |                  | (1,555 | )
|                                                                     |  |                  |        |  
|Balance as of June 30, 2009                                          |  | $                | 0      |  
|                                                                     |  |                  |        |  

In accordance with EITF 96-19,Debtors Accounting for a Modification or Exchange of Debt
Instruments, the terms of the January Exchange Notes entered into on January 20, 2009 were substantially different from the previous terms of the January Exchange Notes. Therefore, this transaction was accounted for as an extinguishment of
debt as set forth in FAS 140,Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. This resulted in a loss on debt extinguishment of $678,000, recognized in the consolidated statements of operations
for the six months ended June 30, 2009. In conjunction with this debt extinguishment, $548,000 of unamortized warrant discount and $130,000 of unamortized debt issuance costs were written off in the consolidated statements of operations for the
six months ended June 30, 2009.

As previously noted, the terms of the January Exchange Notes were amended effective as of the second
amendment date of the notes of March 13, 2009 to fix the conversion price option at $3.00.



15



---

##### Table of Contents

Based on evaluation under EITF 96-19, the terms of the January Exchange Notes, as amended and effective
on March 13, 2009, were determined to be substantially different from the previous terms of the January Exchange Notes. As a result, this March 13, 2009 amendment was accounted for as an extinguishment of debt as set forth in FAS 140,Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. This resulted in a loss on debt extinguishment, recognized in the consolidated statements of operations for the six months ended June 30, 2009.
In conjunction with this debt extinguishment, $3,156,000 of unamortized debt discount and $247,000 of unamortized debt issuance costs were written off in the consolidated statements of operations for the six months ended June 30, 2009. The
Company recorded the fair value of the amended notes at $10,927,000, as of March 13, 2009 which will be amortized to face value using the effective interest method over the remaining term of the notes. Amortization of debt premium of $34,000
and $41,000 was recorded, for the three months ended June 30, 2009 and the period from March 13, 2009 through June 30, 2009, respectively.

On March 13, 2009, the Company entered into a Placement Agency Agreement with Philadelphia Brokerage Corporation (the Placement Agent), as placement agent relating to the issuance and sale to
investors of up to $7,000,000 principal amount of 12.5% Subordinated Convertible Notes due July 1, 2011 (the March Public Notes) convertible into common shares of the Company (the Placement).

The March Public Notes bear interest at the annual rate of 12.5% from March 16, 2009, or the most recent interest payment date to which interest has
been paid or provided for, payable quarterly in arrears on April 1, July 1, October 1 and January 1 of each year, commencing April 1, 2009 to the persons in whose names the March Public Notes are registered at the close of
business on March 15, June 15, September 15 or December 15 (whether or not a business day), as the case may be, preceding the respective interest payment date.

Each note holder of a March Public Note is entitled, at his option, at any time after the close of business on May 15, 2009, to convert the March
Public Notes (or any portion of the principal amount thereof which is $1,000 or an integral multiple thereof) into fully paid and non-assessable common shares of the Company, at a conversion price per share equal to $3.00.

On May 14, 2009, the Company amended the terms of the March Public Notes to fix the conversion price at an amount equal to $3.00 per share of common
stock and to add a covenant stating that the Company shall not issue equity, convertible debt or securities convertible into equity at an amount equal to less than $2.75 per share of common stock (with such $2.75 amount to include the fair value of
any option, warrant or similar right offered by the Company and to be adjusted in the manner identical to the adjustment of the conversion price as provided in the amended agreement) until December 31, 2009. The amendment of the March Public
Notes was effective as of March 16, 2009.

On March 13, 2009, the Company completed an exchange (the March Exchange)
of $1,000,000 principal amount of its 10.0% Notes for the same principal amount of its 12.5% March Exchange Secured Convertible Notes due July 1, 2011 (the March Exchange Notes), pursuant to a note exchange agreement (the
Note Exchange Agreement) by and between the Company and certain holders of the 10.0% Notes (the March Exchange Note holders). The terms of the March Exchange Notes are substantially similar to those of the January Exchange
Notes. The Company recorded the fair value of the amended notes at $1,026,000 as of March 13, 2009 which will be amortized to face value using the effective interest method over the remaining term of such notes. Amortization of debt premium of
$4,000 was recorded for the three months ended June 30, 2009 and the period from March 13, 2009 through June 30, 2009.

In
addition, on March 16, 2009, the Company completed a private placement (the Private Placement) of $6,350,000 principal amount of 12.5% March Cash Secured Convertible Notes due July 1, 2011 (the March Cash
Notes). The terms of the March Cash Notes are substantially similar to the terms of the March Exchange Notes. The Company consummated the Private Placement by entrance into purchase agreements (the Purchase Agreement) with certain
investors (the Private Note holders).

The Company amended the March Exchange Notes (the March Exchange Note
Amendment) and the March Cash Notes (the March Cash Note Amendment) on May 14, 2009. The terms of the March Exchange Note Amendment and March Cash Note Amendment are substantially similar to the terms of the January Exchange
Note Third Amendment. The March Exchange Note Amendment was effective as of March 13, 2009 and the March Cash Note Amendment was effective as of March 16, 2009.

In accordance with EITF 96-19,Debtors Accounting for a Modification or Exchange of Debt Instruments, the terms of the March Exchange Notes entered into on March 13, 2009 were substantially different
to the previous terms of the March Exchange Notes. Therefore, this transaction was accounted for as an extinguishment of debt as set forth in FAS 140,Accounting for Transfers



16



---

##### Table of Contents

and Servicing of Financial Assets and Extinguishments of Liabilities. This resulted in a loss on debt extinguishment of $90,000, recognized in the
consolidated statement of operations in the quarter ended March 31, 2009. In conjunction with this debt extinguishment, $52,000 of unamortized warrant discount and $12,000 of unamortized debt issuance costs were written off in the consolidated
statement of operations in the six months ended June 30, 2009.

On March 16, 2009 the Company called the remaining $11,350,000 of
its 10.0% Secured Promissory Notes due May 1, 2009. This resulted in a loss on debt extinguishment of $125,000, recognized in the consolidated statement of operations in the six months ended June 30, 2009.

On June 24, 2009, the Company entered into a RMB 30,000,000 (or $4,381,000 as of June 24, 2009) loan agreement with Bank of Communication in
China. The term of the loan is June 24, 2009 through May 24, 2011 a 5.4% annual rate of interest paid monthly. The Companys obligations under the debt are secured by assets of Sunstone. The loan does not contain any covenants. As of
June 30, 2009, RMB 30,000,000 (or $4,383,000) is outstanding and is due May 2011.

5. Common Stock Warrants

On February 20, 2009, the Company closed its offering of 559,062 units (the Units), each consisting of (i) two shares of the
Companys common stock, par value $0.001 per share (Common Stock), and (ii) a warrant (Warrant) to purchase one share of Common Stock at an exercise price of $4.00 per share, which exercise price is subject to
potential re-pricing.

If on the 90th day after the closing date (the Re-price Date), the volume weighted average trading price
calculated over the 20 trading days prior to the Re-price Date (the VWAP) of the Common Stock is less than $4.00 per share, the exercise price of the Warrants will be reset to the greater of (i) $1.80 or (ii) the VWAP. The
Warrants are exercisable beginning any time on or after the Re-price Date and expiring on the fifth anniversary of the Closing Date. In no event, shall the number of shares of Common Stock and shares of Common Stock underlying the Warrants exceed
19.99% of the Companys outstanding Common Stock as of February 13, 2009.

The Units were offered by the Company at a purchase
price of $6.40 per Unit (the Offering). As a result of the Offering, the Company issued 1,118,124 shares of Common Stock and 559,062 Warrants. The net proceeds to the Company from the Offering were approximately $3,000,000.

At the date of issuance of the Warrants, the Company determined that the financial instrument constituted a derivative. The fair value of the
derivative was determined to be $838,000, and was recorded as a derivative liability at inception. That amount is being accreted through charges to the consolidated statements of operations using the effective interest method over the term of the
Warrants. At March 31, 2009, the fair value of the derivative was $894,000. The increase in the fair value of the derivative was also recorded in the consolidated statements of operations as a loss on derivative during the period ended
March 31, 2009. The loss on derivatives of $447,000 and $504,000 was recorded, for the three months ended June 30, 2009 and for the period February 20, 2009 through June 30, 2009.

The Company is subject to a derivative warrant liability instrument due to the fact that the related contract is not indexed to its own stock, as
specified by EITF No. 07-5,Determining Whether and Instrument (or Embedded Feature) Is Indexed to an Entitys Own Stock. The derivative is accounted for and classified as a Derivative Liability within the other
liabilities section of the consolidated balance sheet. The change in the fair value of the derivative is included within other income (loss) in the consolidated statements of operations. The change in the fair value of the derivative
instrument affects the Gain on Fair Value of Derivatives line in the cash flows from operating activities section of the consolidated statements of cash flows.

After 90 days from the issuance of the warrants or May 21, 2009, the warrant option reprice provisions expired and the warrant was deemed to be indexed
to its own stock, accordingly the warrant liability was extinguished in the amount of $1,342,000 and recorded as additional paid in capital.

The derivative is not intended to hedge any specific risk exposures, such as fluctuating interest rates, exchange rates, commodity prices, etc. Therefore, the derivative constitutes neither a cash flow hedge, nor a fair value hedge. The
volume of derivative activity relates solely to the derivative warrant liability instrument itself, and changes in fair value thereon.



17



---

##### Table of Contents

Tabular disclosure of the fair value of the derivative instrument in the consolidated balance sheets, and
the effect of the derivative instrument on the consolidated balance sheets follows:



|                                                                 |  |                                          |  |                 
|---------------------------------------------------------------- |  | ---------------------------------------- |  | ----------------
|                                                                 |  | As of June 30, 2009Liability
Derivatives
|                                                                 |  | Balance Sheet Location                   |  | Fair Value      
|                                                                 |  |                                          |  | ($ in thousands)
|Derivatives designated as hedging instruments under FAS 133:     |  |                                          |  |                 
|None                                                             |  |                                          |  |                 
|Derivatives not designated as hedging instruments under FAS 133: |  |                                          |  |                 
|Derivative Warrant Liability                                     |  | None                                     |  |                 
|                                                                 |  |                                          |  |                 
|Total derivatives                                                |  |                                          |  |                 
|                                                                 |  |                                          |  |                 

The effect of the derivative instrument on the consolidated statements of operations for the six
months ended June 30, 2009 follows:



|                                                                 |  |                                                       |  |                                                                                 |      |  
|---------------------------------------------------------------- |  | ----------------------------------------------------- |  | ------------------------------------------------------------------------------- | ---- | -
|                                                                 |  | Location of Gain (Loss) Recognizedin Income Statement |  | Amount of Gain (Loss)Recognized in
IncomeStatementSix Months Ended June 30,2009 |     
|                                                                 |  |                                                       |  | ($ in thousands)                                                                |     
|Derivatives not designated as hedging instruments under FAS 133: |  |                                                       |  |                                                                                 |      |  
|Derivative Warrant Liability                                     |  | Other Income (Expense)                                |  | $                                                                               | (504 | )
|                                                                 |  |                                                       |  |                                                                                 |      |  
|Total                                                            |  |                                                       |  | $                                                                               | (504 | )
|                                                                 |  |                                                       |  |                                                                                 |      |  

The fair value of the warrant liability was determined using the Black Scholes Option Pricing
method. The valuation methodology uses a combination of observable (Level 2) and unobservable (Level 3) inputs in calculating fair value.

As required by FAS 157, assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The table below sets forth a summary of changes in the fair value of the Companys level 3 derivative for the six months ended June 30, 2009:



|                                                      |  |                  |        |  
|----------------------------------------------------- |  | ---------------- | ------ | -
|                                                      |  | ($ in thousands) |       
|Balance as of December 31, 2008                       |  | $                | 0      |  
|Recording of Derivative Liability on Warrant Issuance |  |                  | 838    |  
|Change in Fair Value of Derivative Liability          |  |                  | 504    |  
|Extinguishment of Derivative Liability                |  |                  | (1,342 | )
|                                                      |  |                  |        |  
|Balance as of June 30, 2009                           |  | $                |       |  
|                                                      |  |                  |        |  



18



---

##### Table of Contents

6. Accrued Expenses

Accrued expenses as of June 30, 2009 and December 31, 2008 consist of the following:



|                                            |  |      |        |      |   |       
|------------------------------------------- |  | ---- | ------ | ---- | - | ------
|                                            |  | 2009 |        | 2008
|Accrued salary and related expenses         |  | $    | 1,629  |      | $ | 1,152 
|Accrued professional fees                   |  |      | 344    |      |   | 418   
|Accrued taxes and related expenses          |  |      | 2,032  |      |   | 7,112 
|Accrued social welfare and related expenses |  |      | 1,078  |      |   | 1,409 
|Accrued advertising                         |  |      | 1,477  |      |   | 1,093 
|Accrued travel and entertainment            |  |      | 2,188  |      |   | 881   
|Accrued marketing                           |  |      | 2,407  |      |   | 66    
|Accrued sales office expenses               |  |      | 2,626  |      |   | 823   
|Accrued interest expense                    |  |      | 569    |      |   | 383   
|Accrued other                               |  |      | 851    |      |   | 1,264 
|                                            |  |      |        |      |   |       
|Total Accrued expenses                      |  | $    | 15,201 |      | $ | 14,601
|                                            |  |      |        |      |   |       

7. Shareholders Equity

The following table shows weighted average basic shares for the respective periods:



|                                                                                                                                                                                                                                                                                                                                                   |  |                             |            |                           |   |              |  |      |             |  |   |             
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | --------------------------- | ---------- | ------------------------- | - | ------------ |  | ---- | ----------- |  | - | ------------
|                                                                                                                                                                                                                                                                                                                                                   |  | Three months ended June 30, |            | Six months ended June 30,
|                                                                                                                                                                                                                                                                                                                                                   |  | 2009                        |            | 2008                      |   | 2009         |  | 2008
|Weighted average basic shares                                                                                                                                                                                                                                                                                                                      |  |                             | 41,538,978 |                           |   | 39,510,707   |  |      | 41,154,170  |  |   | 37,303,504  
|                                                                                                                                                                                                                                                                                                                                                  
|The following table shows potential common stock equivalents outstanding to purchase shares of common stock that were included in the computation of
diluted weighted average shares outstanding. The potential common shares related to the convertible notes are included in the computation of the diluted weighted average shares outstanding.
|                                                                                                                                                                                                                                                                                                                                                   |  |                            
|                                                                                                                                                                                                                                                                                                                                                   |  | Three months ended June 30, |            | Six months ended June 30,
|                                                                                                                                                                                                                                                                                                                                                   |  | 2009                        |            | 2008                      |   | 2009         |  | 2008
|Number of shares                                                                                                                                                                                                                                                                                                                                   |  |                             | 9,159,881  |                           |   | 1,339,563    |  |      | 5,720,914   |  |   | 1,415,876   
|Range of exercise price                                                                                                                                                                                                                                                                                                                            |  | $                           | 1.15-$4.00 |                           | $ | 1.15 - $5.84 |  | $    | 1.15- $3.49 |  | $ | 1.15 - $7.48

8. Stock-Based Compensation:

The Companys 2007 Omnibus Equity Compensation Plan (the Plan) which merged with the Companys 2004 Stock Incentive Plan as of April 26, 2007 provides for grants of stock options (incentive
stock options and nonqualified stock options), stock appreciation rights, restricted stock, restricted stock units, performance awards, other stock grants and other stock-based awards to all employees (including employees who are directors or
officers), non-employee directors, consultants and independent contractors of the Company and its affiliates. The Plan authorizes the issuance of up to 5,000,000 shares of the Companys common stock, subject to adjustment, and provides that no
more than 400,000 shares of common stock, subject to adjustment, may be awarded to any one individual in any calendar year if the value of the award is based solely on an increase in the value of shares of the Companys common stock after the
date of grant of the award. The Plan also provides that no more than 100,000 shares of common stock, subject to adjustment, may be awarded to any one individual in any calendar year if the value of the award is not based solely on an increase in the
value of shares of the Companys common stock after the date of grant of the award. Options are granted for a term of ten years and vest over a four year period. Options granted under the Plan from 2005 through June 30, 2009 vest 25% after
the first year of the date of grant and ratably each month over the remaining 36 month period. Options granted in 2004 under the Plan vest 50% after the first two years of the date of hire and ratably each month over the remaining 24 month
period. The Plan is administered by the Companys Compensation Committee. The Compensation Committee has the authority to determine the individuals who will receive grants, the type of grant, the number of shares subject to the grant, the terms
of the grant, the time the grants will be made and the duration of any exercise or restriction period, and has the authority to deal with any other matters arising under the Plan. Options granted under the Plan may be incentive stock
options, which are intended to qualify with the requirements of section 422 of the Internal Revenue Code of 1986, as amended, and nonqualified stock options, which are not intended to so



19



---

##### Table of Contents

qualify. The Companys board of directors may amend or terminate the Plan at any time if required under the Plan, subject to stockholder approval.
Unless terminated earlier by the board of directors or extended by the board of directors, with the approval of the Companys stockholders, no awards may be granted under the Plan after April 25, 2012.

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:



|                        |  |                             |   |  |                           |   |  |      |   |  |           |  
|----------------------- |  | --------------------------- | - |  | ------------------------- | - |  | ---- | - |  | --------- | -
|                        |  | Three months ended June 30, |   |  | Six months ended June 30, |  
|                        |  | 2009                        |   |  | 2008                      |   |  | 2009 |   |  | 2008      |  
|Expected life (years)   |  | 5.0                         |   |  | 5.0                       |   |  | 5.0  |   |  | 5.0       |  
|Risk-free interest rate |  | 1.87                        | % |  | 3.14-3.22                 | % |  | 1.87 | % |  | 2.36-3.22 | %
|Expected Volatility     |  | 78                          | % |  | 55                        | % |  | 78   | % |  | 55        | %
|Expected Dividend yield |  | 0.00                        | % |  | 0.00                      | % |  | 0.00 | % |  | 0.00      | %

The weighted average estimated fair value of the options granted for the three and six months
ended June 30, 2009 was $2.21. The weighted average estimated fair value of the options granted for the three and six months ended June 30, 2008 was $3.70 and $3.83, respectively.

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are
fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock volatility. Because the Companys employee stock options have characteristics significantly different from
those of traded options, and because changes in subjective input assumptions can materially affect the fair value estimate, in managements opinion, the existing models do not necessarily provide a reliable single measure of the fair value of
its employee stock options. Compensation cost which is based on the fair value of options granted is recognized on a straight line basis over the service period.

A summary of the options issued by the Company for the six months ended June 30, 2009 is as follows:



|                               |  |           |  |                                        |       |                                                    |      |                         |   |          
|------------------------------ |  | --------- |  | -------------------------------------- | ----- | -------------------------------------------------- | ---- | ----------------------- | - | ---------
|                               |  | Options   |  | Weighted-AverageExercisePriceper Share |       | Weighted-AverageRemainingContractualTerm(in years) |      | AggregateIntrinsicValue
|Outstanding on January 1, 2009 |  | 3,157,801 |  | $                                      | 5.17  |                                                    | 7.18 |                         | $ | 5,796,000
|Granted                        |  |          |  |                                        |      |                                                    |      |                         |   |         
|Exercised                      |  |          |  |                                        |      |                                                    |      |                         |   |         
|Canceled                       |  | 605       |  |                                        | 10.90 |                                                    |      |                         |   |          
|                               |  |           |  |                                        |       |                                                    |      |                         |   |          
|Outstanding on March 31, 2009  |  | 3,157,196 |  | $                                      | 5.17  |                                                    | 6.94 |                         | $ | 2,172,000
|Granted                        |  | 310,000   |  |                                        | 3.49  |                                                    |      |                         |   |          
|Exercised                      |  |          |  |                                        |      |                                                    |      |                         |   |          
|Canceled                       |  | 4,919     |  |                                        | 7.45  |                                                    |      |                         |   |          
|                               |  |           |  |                                        |       |                                                    |      |                         |   |          
|Outstanding on June 30, 2009   |  | 3,462,277 |  |                                        | 5.02  |                                                    | 6.96 |                         |   | 4,828,000
|                               |  |           |  |                                        |       |                                                    |      |                         |   |          
|Exercisable on June 30, 2009   |  | 2,187,439 |  |                                        | 3.90  |                                                    | 5.95 |                         |   | 3,358,000
|                               |  |           |  |                                        |       |                                                    |      |                         |   |          

The total fair value of shares vested during the three months ended June 30, 2009 was
$1,021,000. A summary of the status of the Companys non-vested shares as of June 30, 2009 is presented below:



|                             |  |                 |  |                                      |     
|---------------------------- |  | --------------- |  | ------------------------------------ | ----
|                             |  | NonvestedShares |  | Weighted-AverageGrant-Date FairValue
|Nonvested at January 1, 2009 |  | 1,354,271       |  | $                                    | 4.57
|Granted                      |  | 310,000         |  |                                      | 2.21
|Vested                       |  | 383,909         |  |                                      | 4.16
|Canceled                     |  | 5,524           |  |                                      | 5.08
|                             |  |                 |  |                                      |     
|Non-vested at June 30, 2009  |  | 1,274,838       |  | $                                    | 4.12
|                             |  |                 |  |                                      |     



20



---

##### Table of Contents

The unrecognized share-based compensation cost related to unvested stock options at June 30, 2009 is
$4,814,000 and will be recognized over a weighted average of 2.5 years.

9. Related Party Transactions

On July 5, 2008, the Company acquired 63.3% of Rongheng. Based upon the Share Transfer and Capital Increase Agreement related to Rongheng, the
Company agreed to a guarantee arrangement for the outstanding debt due to Rongheng International Trade Co. Ltd of Orient International Holding Co. (RHIT) and Shanghai CAS Shenglongda Biotech Group Co, Ltd (Shenglongda). The
amounts due to RHIT and Shenglongda are summarized as follows:



|                                |  |                         |      
|------------------------------- |  | ----------------------- | -----
|                                |  | Balance atJune 30, 2009
|($ amounts in thousands)        |  | ($ in thousands)       
|Amounts due to related parties: |  |                         |      
|Due to RHIT                     |  | $                       | 1,359
|Due to Shenglongda              |  |                         | 387  
|                                |  |                         |      
|                                |  | $                       | 1,746
|                                |  |                         |      

During the three and six months ended June 30, 2009, the Company sold $360,000 and $4,102,000,
respectively, in pharmaceutical products to related party entities of the Companys President, Zhiqiang Han (Han).

During
the three and six months ended June 30, 2009 the Company leased office space in Beijing from an entity controlled by Zhijun Tong (Tong), a Company director, for $23,000 and $46,000, respectively. At June 30, 2009, the Company
had balances due from and due to Han.

The balances due from and due to Han are summarized as follows:



|                                                        |  |                         |      
|------------------------------------------------------- |  | ----------------------- | -----
|                                                        |  | Balance atJune 30, 2009
|                                                        |  | ($ in thousands)       
|Amounts due from related parties:                       |  |                         |      
|Accounts receivable due from entities controlled by Han |  | $                       | 1,259
|                                                        |  |                         |      
|Amounts due to related parties:                         |  |                         |      
|Due to Han and entities controlled by Han               |  | $                       | 474  
|                                                        |  |                         |      
|                                                        |  | $                       | 474  
|                                                        |  |                         |      

During the six months ended June 30, 2009 the Company received an advance payment for the
purchase of inventory of $438,000 from Shengda. The $438,000 remains outstanding as of June 30, 2009.

10. Subsequent Event

On August 3, 2009, the Company entered into a Share Purchase Agreement with Alliance Unichem for the sale of its 20% ownership in Alliance BMP
Limited, an investment vehicle based in the United Kingdom. The total sale price of $15.1 million approximates the carrying value of the investment at June 30, 2009 and payments will be received over a one year period.



21



---

##### Table of Contents

|ITEM 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations
|------- | -------------------------------------------------------------------------------------

The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in
conjunction with the financial statements and notes thereto included in the Companys Annual Report on Form 10-K for the year ended December 31, 2008.

Forward-Looking Statements

Certain of the statements contained in this Managements Discussion
and Analysis of Financial Condition and Results of Operations (MD&A) and elsewhere in this report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the
Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements are based on managements current expectations and are subject to uncertainty and changes in
circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include, among others, statements regarding derivative liabilities and accounting treatment
thereof, statements addressing managements views with respect to future financial and operating results, our ability to obtain an increased market share in the Chinese pharmaceutical marketing and distribution markets, the dependence of our
future success on obtaining additional promotional and market research agreements and licensing rights for China, the significance of our acquisition of Wanwei and Sunstone, our cash and cash equivalents investments, our anticipated use of cash
resources, our ability to fund our current level of operations through our cash and cash equivalents, our hiring goals for the next twelve months, our capital requirements and the possible impact on us if we are unable to satisfy these requirements,
our approaches to raise additional funds and our expectation to continue to pursue strategic acquisitions in the near future. Various factors, including competitive pressures, success of integration, market interest rates, changes in customer mix,
changes in pharmaceutical manufacturers pricing and distribution policies or practices, regulatory changes, changes in the Peoples Republic of Chinas policies, customer defaults or insolvencies, acquisition of businesses that do
not perform as we expect or that are difficult for us to integrate or control, adverse resolution of any contract or other disputes with customers and suppliers, or the loss of one or more key customer or supplier relationships, could cause actual
outcomes and results to differ materially from those described in forward-looking statements. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking
statements are set forth in this report in Part II, Item 1A. Risk Factors in this quarterly report on Form 10-Q and in Part I, Item 1A. Risk Factors  Risks Relating to Our Business in our Annual
Report on Form 10-K for the year ended December 31, 2008.

Overview

BMP Sunstone Corporation, a Delaware corporation (the Company), is a specialty pharmaceutical company with over-the-counter, or OTC,
prescription drugs, manufacturing, marketing and distribution based in China. Through our subsidiary, Sunstone (Tangshan) Pharmaceutical Co., Ltd., or Sunstone, we manufacture, market and distribute OTC products in China. In addition, through
Beijing Medpharm Co. Ltd., or BMP China, Beijing Wanwei Pharmaceutical Co., Ltd., or Wanwei and Shanghai Rongheng Pharmaceutical Company, or Rongheng, we offer to foreign and domestic pharmaceutical manufacturers in China, services focused primarily
on marketing and promotional services and distribution services. The Company, Sunstone, BMP China, Wanwei and Rongheng are collectively referred to as the Company, we or our.

Financial Overview

Our future success will depend on
the continued growth of Sunstones OTC and our Licensed Products. Sunstones sales and operating profit growth rate historically has been higher than Chinas pharmaceutical industry average growth rate. Sunstones strong brands
of Goodbaby and Confort have helped Sunstone expand its revenue and increase its profitability. Sunstones brand name and product portfolio are critical to the continued success of its business. Sunstone has been
broadening its products pipeline through internal development, acquisition and licensing of the domestic products. Sunstones revenues are seasonal with the majority of sales related to cough, cold and flu products. Through the acquisition of
Shengda we now have antibiotic products in our Goodbaby brand of products. The consumption of antibiotics has the highest market share for the pediatric drugs market in China. In addition, we expect the acquisition of Shengda will enrich our product
brands.



22



---

##### Table of Contents

We believe our Licensed Products segment will continue to have significant continued growth. During 2008
and 2009, we have made significant adjustments to strengthen our sales and marketing capability by focusing on obstetrics and gynecology. In addition, we have pursued a strategy of consolidating our sales and marketing teams so that we can achieve
higher growth and profitability. In addition, we are actively searching for new pharmaceutical products from foreign pharmaceutical companies for licensing into China.

Acquisitions

On December 19, 2008, Sunstone entered into an Equity Transfer Agreement with
Beijing Penn Pharmaceutical Sci-Tech Development Co., Ltd. (Beijing Penn) to purchase 50% of the outstanding equity interests of Zhangjiakou Shengda Pharmaceutical Co., Ltd. (Shengda) for RMB 20.0 million (or $2,920,000
as of February 16, 2009) in cash. On February 16, 2009 we received the business license of Shengda and closed on the acquisition. The Company has changed its name to Sunstone Shengda (Zhangjiakou) Pharmaceutical Co., Ltd.

The purchase price is payable in installments:



| |  |  | RMB 6 million (or $875,000 as of December 31, 2008) was payable within 15 business days following the signing of the Equity Transfer Agreement and was paid as
of December 31, 2008;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | RMB 14 million (or $2,045,000 as of June 30, 2009) is payable in five equal installments on the second, fourth, sixth, eighth and tenth month anniversary
following the closing of the transactions contemplated by the Equity Transfer Agreement.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pursuant to the Equity Transfer
Agreement, the Company purchased 50% of the outstanding equity interests of Shengda from Beijing Penn. Shengda is a Sino-foreign joint venture corporation with a contract period of 30 years. Following the transactions as completed by the Equity
Transfer Agreement, the Company is one of three shareholders of Shengda. The investment in Shengda was accounted for in accordance with APB 18 under the equity method of accounting. Our total investment in Shengda was $3,003,000 as of June 30,
2009, of which we had paid $1,696,000. There were no acquisition costs incurred during the three or six months ended June 30, 2009.

On April 12, 2009, Sunstone entered into a joint venture agreement with Tangshan Yangguang Fulai Business Consultants Co., Ltd. (Tangshan SunshineFly) to establish Taiyangshi Fulai Tangshan Pharmaceutical Co., Ltd. (Sunstone Fulai) located
in Yutian County, Tangshan. Sunstone Fulai is owned 70% by Sunstone and 30% by Tangshan SunshineFly. The joint venture agreement requires Sunstone to inject RMB 35 million (or $5.2 million as of April 15, 2009) and Tangshan SunshineFly to
contribute technology with an estimated value of RMB 15 million (or $2.2 million as of April 15, 2009). On April 16, 2009, Sunstone Fulai received the business license.

Sunstones capital contribution is payable in installments:



| |  |  | RMB 10 million (or $1,462,000 as of April 15, 2009) was paid April 15, 2009;
| | - |  | ----------------------------------------------------------------------------



| |  |  | RMB 10 million (or $1,461,000 as of July 21, 2009) was paid as of July 21, 2009;
| | - |  | --------------------------------------------------------------------------------



| |  |  | RMB 10 million (or $1,461,000 as of June 30, 2009) is payable December 15, 2009; and
| | - |  | ------------------------------------------------------------------------------------



| |  |  | RMB 5 million is (or $730,000 as of June 30, 2009) payable December 15, 2010.
| | - |  | -----------------------------------------------------------------------------

In acquiring our 70 percent interest in Sunstone Fulai, Sunstone has agreed to inject RMB 35 million of which RMB 10 million was injected as of
June 30, 2009. Tangshan SunshineFly will contribute production technology at a later date once the manufacturing facility is completed. For financial reporting purposes, we have accounted for Sunstone Fulai as a consolidated subsidiary from
April 16, 2009 through June 30, 2009.

The noncontrolling interest of Tangshan SunshineFly represents the fair value of 30
percent of Sunstones cash injection in April 2009 or RMB 3 million (or $439,000 as of April 16, 2009) adjusted for 30% of the net loss of Sunstone Fulai. For the period April 16, 2009 through June 30, 2009, Sunstone Fulai
generated a loss of $52,000.

Sale of Alliance BMP Limited

On August 3, 2009, the Company entered into a Share Purchase Agreement with Alliance Unichem for the sale of its 20% ownership in Alliance BMP Limited, an investment vehicle based in the United Kingdom. The total
sale price was $15.1 million, approximating the carrying value of the investment at June 30, 2009. The payments will be received over a one year period.



23



---

##### Table of Contents

Liquidity and Capital Resources

Cash

As of June 30, 2009, we had unrestricted cash and cash equivalents of approximately $8.9
million which represented 3.8% of our total assets. Our cash and cash equivalents are highly liquid investments with a maturity of three months or less at the time of purchase and are primarily invested in short-term money market instruments and
investments. However, we do not anticipate any losses with respect to such cash balances because the balances are invested in government backed securities.

Long Term Debt

On January 20, 2009, BMP Sunstone Corporation (the Parent) completed an exchange (the
Exchange) of $10,650,000 in principal amount of its 10.0% senior secured promissory notes (the 10.0% Notes) for $10,650,000 in principal amount of its 12.5% secured convertible notes (the January Exchange Notes),
pursuant to note exchange agreements (the Note Exchange Agreements) by and between the Company and certain holders of the 10.0% Notes (the Note holders). Following the Exchange, $12,350,000 in principal amount of 10.0% Notes
remained outstanding.

Pursuant to the Note Exchange Agreements, the Company issued the January Exchange Notes in the aggregate principal
amount of $10,650,000 to the Note holders. The January Exchange Notes bear interest at a rate of 12.5% per annum, payable quarterly in arrears beginning on April 1, 2009. The January Exchange Notes have a maturity date of July 1,
2011. The accrued but unpaid interest on the 10.0% Notes prior to the Exchange was paid to the Note holders participating in the Exchange on April 1, 2009.

Based upon the original terms of the January Exchange Notes, a Note holder may convert its January Exchange Note into fully paid and non-assessable shares of common stock, par value $0.001 per share (the Common
Shares), of the Company from time to time at a conversion price, subject to certain adjustments, equal to $5.00. If the Company issues Common Shares in one or more offerings to investors on or prior to September 15, 2009 (other than any
offerings following the issuance of Common Shares in one or more offerings to investors resulting in the receipt of proceeds (net of all commissions) by the Company in an aggregate amount of at least $16,000,000), the conversion price will equal the
lesser of (i) $5.00 or (ii) 115% of the lowest price per Common Share for which the Company sells Common Shares in any offering.

Notwithstanding the foregoing, pursuant to certain amendments to the January Exchange Notes, dated as of January 29, 2009, if the conversion price of the January Exchange Notes would result, upon conversion of all such notes, in the
issuance of Common Shares in amount equal to or greater than 8,049,282 Common Shares (which was equal to 20.00% of 40,246,410, which was the number of outstanding Common Shares on the date thereof), the conversion price shall be increased to $1.33
(which is equal to the principal amount of the January Exchange Notes of $10,650,000 divided by 8,049,282 increased to the nearest whole cent), which would result, upon conversion of all of the January Exchange Notes, in the issuance of Common
Shares in an aggregate amount less than 20.00% of the outstanding Common Shares on the date thereof. The January Exchange Notes were further amended by that certain January Exchange Note Second Amendment (as defined below) and that certain January
Exchange Note Third Amendment (as defined below).

At the date of issuance of the January Exchange Notes , the Company was subject to the
terms of an embedded derivative instrument due to the fact that the related contract was not indexed to its own stock, as specified by EITF No. 07-5,Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entitys Own
Stock.

The Company determined that the convertible note instrument contained an embedded derivative. The fair value of the
embedded derivative was determined to be $3,262,000, and was recorded as a derivative liability at inception. That amount is being accreted through charges to the consolidated statements of operations using the effective interest method over the
period of the January Exchange Notes. At March 13, 2009, the date of the January Exchange Note amendment, the fair value of the derivative was $1,555,000. The decrease in the fair value of the derivative between January 20, 2009 and
March 13, 2009 was recorded in the consolidated statements of operations as a gain on derivative during the quarter ended March 31, 2009.



24



---

##### Table of Contents

As of March 13, 2009, the January Exchange Notes were amended to remove the aforementioned
down-round clause relating to offerings to investors on or prior to September 15, 2009, so that the conversion price, subject to certain adjustments, became fixed at $3.00.

The Company amended the January Exchange Notes (the January Exchange Notes Second Amendment) such that the definition of certain terms and
the mechanics of conversion of the January Exchange Notes parallel those in the March Exchange Notes and to restrict the issuance of Company securities to officers and directors of the Company below an effective price of $3.00 per common share. A
Note holder may convert its January Exchange Note into fully paid and non-assessable shares of common stock, par value $0.001 per share (the Common Shares), of the Company from time to time at a conversion price, subject to certain
adjustments, equal to $3.00. The Company further amended the January Exchange Notes on May 14, 2009 (the January Exchange Notes Third Amendment) such that the conversion price was set at an amount equal to $3.00 per share of common
stock and to add a covenant stating that the Company shall not issue equity, convertible debt or securities convertible into equity at an amount equal to or less than $2.75 per share of common stock (with such $2.75 amount to include the fair value
of any option, warrant or similar right offered by the Company and to be adjusted in the manner identical to the adjustment of the conversion price as provided in amended note agreement of the January Exchange Notes) until December 31, 2009.
The January Exchange Notes Third Amendment was effective as of March 13, 2009.

As of March 13, 2009, the derivative liability
was extinguished and recorded as additional paid-in capital, in accordance with EITF Issue No. 06-7,Issuers Accounting for a Previously Bifurcated Conversion Option in a Convertible Debt Instrument When the Conversion Option No Longer
Meets the Bifurcation Criteria in FASB Statement No. 133.

The derivative was not intended to hedge any specific risk exposures,
such as fluctuating interest rates, exchange rates, commodity prices, etc. Therefore, the derivative constituted neither a cash flow hedge, nor a fair value hedge. The volume of derivative activity relates solely to the embedded derivative
instrument itself, and changes in fair value thereon.

Tabular disclosure of the fair value of the derivative instrument in the
consolidated balance sheets, and the effect of the derivative instrument on the consolidated balance sheets follows:



|                                                                 |  |                                          |  |                 
|---------------------------------------------------------------- |  | ---------------------------------------- |  | ----------------
|                                                                 |  | As of June 30, 2009Liability Derivatives
|                                                                 |  | Balance Sheet Location                   |  | Fair Value      
|                                                                 |  |                                          |  | ($ in thousands)
|Derivatives designated as hedging instruments under FAS 133:     |  |                                          |  |                 
|None                                                             |  |                                          |  |                 
|Derivatives not designated as hedging instruments under FAS 133: |  |                                          |  |                 
|Embedded Derivative                                              |  | None                                     |  |                 
|                                                                 |  |                                          |  |                 
|Total derivatives                                                |  |                                          |  |                 
|                                                                 |  |                                          |  |                 

The effect of the derivative instrument on the consolidated statements of operations for the six
months ended June 30, 2009 follows:



|                                                                 |  |                                                       |  |                                                                                         |      
|---------------------------------------------------------------- |  | ----------------------------------------------------- |  | --------------------------------------------------------------------------------------- | -----
|                                                                 |  | Location of Gain (Loss) Recognized inIncome Statement |  | Amount of Gain (Loss)Recognized in IncomeStatement for
theSix Months Ended June 30,2009
|                                                                 |  |                                                       |  | ($ in thousands)                                                                       
|Derivatives not designated as hedging instruments under FAS 133: |  |                                                       |  |                                                                                         |      
|Embedded Derivative                                              |  | Other Income (Expense)                                |  | $                                                                                       | 1,707
|                                                                 |  |                                                       |  |                                                                                         |      
|Total                                                            |  |                                                       |  | $                                                                                       | 1,707
|                                                                 |  |                                                       |  |                                                                                         |      



25



---

##### Table of Contents

The fair value of the derivative liability was determined using the Black Scholes Option Pricing method.
The valuation methodology uses a combination of observable (Level 2) and unobservable (Level 3) inputs in calculating fair value. As required by FAS 157, assets are classified in their entirety based on the lowest level of input that is significant
to the fair value measurement.

The table below sets forth a summary of changes in the fair value of the Companys level 3 derivative
for the six months ended June 30, 2009.



|                                                                     |  |                  |        |  
|-------------------------------------------------------------------- |  | ---------------- | ------ | -
|                                                                     |  | ($ in thousands) |       
|Balance as of December 31, 2008                                      |  | $                | 0      |  
|Record Derivative Liability on Conversion Option at January 20, 2009 |  |                  | 3,262  |  
|Change in Fair Value of Derivative Liability                         |  |                  | (1,707 | )
|Extinguishment of Derivative Liability                               |  |                  | (1,555 | )
|                                                                     |  |                  |        |  
|Balance as of June 30, 2009                                          |  | $                | 0      |  
|                                                                     |  |                  |        |  

In accordance with EITF 96-19,Debtors Accounting for a Modification or Exchange of Debt
Instruments, the terms of the January Exchange Notes entered into on January 20, 2009 were substantially different from the previous terms of the January Exchange Notes. Therefore, this transaction was accounted for as an extinguishment of
debt as set forth in FAS 140,Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. This resulted in a loss on debt extinguishment of $678,000, recognized in the consolidated statements of operations
for the six months ended June 30, 2009. In conjunction with this debt extinguishment, $548,000 of unamortized warrant discount and $130,000 of unamortized debt issuance costs were written off in the consolidated statements of operations for the
six months ended June 30, 2009.

As previously noted, the terms of the January Exchange Notes were amended effective as of the second
amendment date of the notes of March 13, 2009 to fix the conversion price option at $3.00.

Based on evaluation under EITF 96-19, the
terms of the January Exchange Notes, as amended and effective on March 13, 2009, were determined to be substantially different from the previous terms of the January Exchange Notes. As a result, this March 13, 2009 amendment was accounted
for as an extinguishment of debt as set forth in FAS 140,Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. This resulted in a loss on debt extinguishment, recognized in the consolidated statements
of operations for the six months ended June 30, 2009. In conjunction with this debt extinguishment, $3,156,000 of unamortized debt discount and $247,000 of unamortized debt issuance costs were written off in the consolidated statements of
operations for the six months ended June 30, 2009. The Company recorded the fair value of the amended notes at $10,927,000, as of March 13, 2009 which will be amortized to face value using the effective interest method over the remaining
term of the notes. Amortization of debt premium of $34,000 and $41,000 was recorded, for the three months ended June 30, 2009 and the period from March 13, 2009 through June 30, 2009 respectively.

On March 13, 2009, the Company entered into a Placement Agency Agreement with Philadelphia Brokerage Corporation (the Placement Agent),
as placement agent relating to the issuance and sale to investors of up to $7,000,000 principal amount of 12.5% Subordinated Convertible Notes due July 1, 2011 (the March Public Notes) convertible into common shares of the Company
(the Placement).

The March Public Notes bear interest at the annual rate of 12.5% from March 16, 2009, or the most recent
interest payment date to which interest has been paid or provided for, payable quarterly in arrears on April 1, July 1, October 1 and January 1 of each year, commencing April 1, 2009 to the persons in whose names the March
Public Notes are registered at the close of business on March 15, June 15, September 15 or December 15 (whether or not a business day), as the case may be, preceding the respective interest payment date.

Each note holder of a March Public Note is entitled, at his option, at any time after the close of business on May 15, 2009, to convert the March
Public Notes (or any portion of the principal amount thereof which is $1,000 or an integral multiple thereof) into fully paid and non-assessable common shares of the Company, at a conversion price per share equal to $3.00.

On May 14, 2009, the Company amended the terms of the March Public Notes to fix the conversion price at an amount equal to $3.00 per share of common
stock and to add a covenant stating that the Company shall not issue equity, convertible debt or securities convertible into equity at an amount equal to less than $2.75 per share of common stock (with such $2.75 amount to include the fair value of
any option, warrant or similar right offered by the Company and to be adjusted in the manner identical to the adjustment of the conversion price as provided in the amended agreement) until December 31, 2009. The amendment of the March Public
Notes was effective as of March 16, 2009.



26



---

##### Table of Contents

On March 13, 2009, the Company completed an exchange (the March Exchange) of $1,000,000
principal amount of its 10.0% Notes for the same principal amount of its 12.5% March Exchange Secured Convertible Notes due July 1, 2011 (the March Exchange Notes), pursuant to a note exchange agreement (the Note Exchange
Agreement) by and between the Company and certain holders of the 10.0% Notes (the March Exchange Note holders). The terms of the March Exchange Notes are substantially similar to those of the January Exchange Notes. The Company
recorded the fair value of the amended notes at $1,026,000 as of March 13, 2009 which will be amortized to face value using the effective interest method over the remaining term of such notes. Amortization of debt premium of $4,000 was recorded
for the three months ended June 30, 2009 and the period from March 13, 2009 through June 30, 2009.

In addition, on
March 16, 2009, the Company completed a private placement (the Private Placement) of $6,350,000 principal amount of 12.5% March Cash Secured Convertible Notes due July 1, 2011 (the March Cash Notes). The terms
of the March Cash Notes are substantially similar to the terms of the March Exchange Notes. The Company consummated the Private Placement by entrance into purchase agreements (the Purchase Agreement) with certain investors (the
Private Note holders).

The Company amended the March Exchange Notes (the March Exchange Note Amendment) and the
March Cash Notes (the March Cash Note Amendment) on May 14, 2009. The terms of the March Exchange Note Amendment and March Cash Note Amendment are substantially similar to the terms of the January Exchange Note Third Amendment. The
March Exchange Note Amendment was effective as of March 13, 2009 and the March Cash Note Amendment was effective as of March 16, 2009.

In accordance with EITF 96-19,Debtors Accounting for a Modification or Exchange of Debt Instruments, the terms of the March Exchange Notes entered into on March 13, 2009 were substantially different to the previous terms
of the March Exchange Notes. Therefore, this transaction was accounted for as an extinguishment of debt as set forth in FAS 140,Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. This resulted in a
loss on debt extinguishment of $90,000, recognized in the consolidated statement of operations in the quarter ended March 31, 2009. In conjunction with this debt extinguishment, $52,000 of unamortized warrant discount and $12,000 of unamortized
debt issuance costs were written off in the consolidated statement of operations in the six months ended June 30, 2009.

On
March 16, 2009 the Company called the remaining $11,350,000 of its 10.0% Secured Promissory Notes due May 1, 2009. This resulted in a loss on debt extinguishment of $125,000, recognized in the consolidated statement of operations in the
six months ended June 30, 2009.

On June 24, 2009, the Company entered into a RMB 30,000,000 (or $4,381,000 as of June 24, 2009)
loan agreement with Bank of Communication in China. The term of the loan is June 24, 2009 through May 24, 2011 a 5.4% annual rate of interest and pays interest monthly. The Companys obligations under the debt are secured by assets of
Sunstone. The loan does not contain any covenants. As of June 30, 2009, RMB 30,000,000 (or $4,383,000) is outstanding and is due May 2011.

Common
Stock Warrants

On February 20, 2009, the Company closed its offering of 559,062 units (the Units), each consisting of
(i) two shares of the Companys common stock, par value $0.001 per share (Common Stock), and (ii) a warrant (Warrant) to purchase one share of Common Stock at an exercise price of $4.00 per share, which
exercise price is subject to potential re-pricing.

If on the 90th day after the closing date (the Re-price Date), the volume
weighted average trading price calculated over the 20 trading days prior to the Re-price Date (the VWAP) of the Common Stock is less than $4.00 per share, the exercise price of the Warrants will be reset to the greater of (i) $1.80
or (ii) the VWAP. The Warrants are exercisable beginning any time on or after the Re-price Date and expiring on the fifth anniversary of the Closing Date. In no event, shall the number of shares of Common Stock and shares of Common Stock
underlying the Warrants exceed 19.99% of the Companys outstanding Common Stock as of February 13, 2009.

The Units were offered
by the Company at a purchase price of $6.40 per Unit (the Offering). As a result of the Offering, the Company issued 1,118,124 shares of Common Stock and 559,062 Warrants. The net proceeds to the Company from the Offering were
approximately $3,000,000.



27



---

##### Table of Contents

At the date of issuance of the Warrants, the Company determined that the financial instrument constituted
a derivative. The fair value of the derivative was determined to be $838,000, and was recorded as a derivative liability at inception. That amount is being accreted through charges to the consolidated statements of operations using the effective
interest method over the term of the Warrants. At March 31, 2009, the fair value of the derivative was $894,000. The increase in the fair value of the derivative was also recorded in the consolidated statements of operations as a loss on
derivative during the period ended March 31, 2009. The loss on derivatives of $447,000 and $504,000 was recorded, for the three months ended June 30, 2009 and for the period February 20, 2009 through June 30, 2009.

The Company is subject to a derivative warrant liability instrument due to the fact that the related contract is not indexed to its own stock, as
specified by EITF No. 07-5,Determining Whether and Instrument (or Embedded Feature) Is Indexed to an Entitys Own Stock. The derivative is accounted for and classified as a Derivative Liability within the other
liabilities section of the consolidated balance sheet. The change in the fair value of the derivative is included within other income (loss) in the consolidated statements of operations. The change in the fair value of the derivative
instrument affects the Gain on Fair Value of Derivatives line in the cash flows from operating activities section of the consolidated statements of cash flows.

After 90 days from the issuance of the warrants, or May 21, 2009 the warrant option reprice provisions expired and the warrant was deemed to be indexed
to its own stock, accordingly the warrant liability was extinguished in the amount of $1,342,000 and recorded as additional paid capital.

The derivative is not intended to hedge any specific risk exposures, such as fluctuating interest rates, exchange rates, commodity prices, etc. Therefore, the derivative constitutes neither a cash flow hedge, nor a fair value hedge. The
volume of derivative activity relates solely to the derivative warrant liability instrument itself, and changes in fair value thereon.

Tabular disclosure of the fair value of the derivative instrument in the consolidated balance sheets, and the effect of the derivative instrument on the consolidated balance sheets follows:



|                                                                 |  |                                          |  |                 
|---------------------------------------------------------------- |  | ---------------------------------------- |  | ----------------
|                                                                 |  | As of June 30, 2009Liability Derivatives
|                                                                 |  | Balance Sheet Location                   |  | Fair Value      
|                                                                 |  |                                          |  | ($ in thousands)
|Derivatives designated as hedging instruments under FAS 133:     |  |                                          |  |                 
|None                                                             |  |                                          |  |                 
|Derivatives not designated as hedging instruments under FAS 133: |  |                                          |  |                 
|Derivative Warrant Liability                                     |  | None                                     |  |                 
|                                                                 |  |                                          |  |                 
|Total derivatives                                                |  |                                          |  |                 
|                                                                 |  |                                          |  |                 

The effect of the derivative instrument on the consolidated statements of operations for the six
months ended June 30, 2009 follows:



|                                                                 |  |                                                       |  |                                                                                 |      |  
|---------------------------------------------------------------- |  | ----------------------------------------------------- |  | ------------------------------------------------------------------------------- | ---- | -
|                                                                 |  | Location of Gain (Loss) Recognizedin Income Statement |  | Amount of Gain (Loss)Recognized in
IncomeStatementSix Months Ended June 30,2009 |     
|                                                                 |  |                                                       |  | ($ in thousands)                                                                |     
|Derivatives not designated as hedging instruments under FAS 133: |  |                                                       |  |                                                                                 |      |  
|Derivative Warrant Liability                                     |  | Other Income (Expense)                                |  | $                                                                               | (504 | )
|                                                                 |  |                                                       |  |                                                                                 |      |  
|Total                                                            |  |                                                       |  | $                                                                               | (504 | )
|                                                                 |  |                                                       |  |                                                                                 |      |  

The fair value of the warrant liability was determined using the Black Scholes Option Pricing
method. The valuation methodology uses a combination of observable (Level 2) and unobservable (Level 3) inputs in calculating fair value.

As required by FAS 157, assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.



28



---

##### Table of Contents

The table below sets forth a summary of changes in the fair value of the Companys level 3
derivative for the six months ended June 30, 2009:



|                                                      |  |                  |        |  
|----------------------------------------------------- |  | ---------------- | ------ | -
|                                                      |  | ($ in thousands) |       
|Balance as of December 31, 2008                       |  | $                | 0      |  
|Recording of Derivative Liability on Warrant Issuance |  |                  | 838    |  
|Change in Fair Value of Derivative Liability          |  |                  | 504    |  
|Extinguishment of Derivative Liability                |  |                  | (1,342 | )
|                                                      |  |                  |        |  
|Balance as of June 30, 2009                           |  | $                |       |  
|                                                      |  |                  |        |  

Cash Flow

We anticipate that our June 30, 2009 balance of approximately $8,901,000 in unrestricted cash and cash equivalents and $15.1 million cash provided as a result of the August 3, 2009 transaction with Alliance
Unichem will be sufficient to fund our current level of operations for at least the next 12 months. Our future capital requirements will depend on many factors, including those factors described in Part II, Item 1A. Risk
Factors in this quarterly report on Form 10-Q and in Part I, Item 1A. Risk Factors  Risks Relating to Our Business in our Annual Report on Form 10-K for the year ended December 31, 2008 as well as our ability
to maintain our existing cost structure and return on sales, fund obligations for additional capital that will occur on additional product licenses and acquisitions and execution of our business and strategic plans as currently conceived.

Net cash used in operating activities was $1,396,000 for the six months ended June 30, 2009. This amount reflected our loss of
$3,706,000, offset by $7,866,000 in net non-cash charges including loss on early extinguishment of debt of $4,573,000, gain on fair value of derivatives of $1,204,000, amortization of intangible assets of $1,772,000, amortization of debt discount
and debt issuance costs of $630,000, stock based compensation expense of $1,184,000, depreciation and amortization of equipment and leasehold improvements of $1,153,000, decrease in deferred taxes of $223,000, equity method investment income of
$82,000, loss on disposal of asset of $79,000 and noncontrolling interest of $16,000. In addition, we generated $5,048,000 of operating cash as result in changes in certain of our operating assets and liabilities during the six months ended
June 30, 2009. The most significant changes were the increase in accrued expenses of $1,025,000 and decreases in other assets of $305,000, inventory of $804,000 and notes receivable of $2,914,000. Offsetting these changes were increases in
accounts receivable of $6,873,000, VAT receivable of $219,000, other receivables of 185,000 and decreases in accounts payable of $2,195,000 and due to related parties of $1,132,000.

Cash used in investing activities was $3,580,000 and reflects the acquisition of property, plant and equipment of $2,762,000 and the payment for Shengda
of $818,000.

Net cash used in financing activities was $2,072,000, which consisted of proceeds from the exercise of warrants of $68,000,
net proceeds from the issuance of common stock of $2,999,000, proceeds from the issuance of long term debt of $12,031,000, offset by the repayment of long term debt of $11,350,000 net payments on bank borrowings of $5,407,000 and the increase of
restricted cash of $413,000.

Results of Operations

Critical Accounting Policies

Our managements discussion and analysis of our financial condition and results of
operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and
assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets or liabilities as of the dates of the financial statements as well as the reported revenues and expenses during the reporting periods. On
an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and various other factors and assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results might differ materially from these estimates under different assumptions or conditions.



29



---

##### Table of Contents

Our critical accounting policies are described in Managements Discussion and Analysis included in
our Annual Report on Form 10-K for the year ended December 31, 2008. There have been no changes in these accounting policies.

Our
significant accounting policies are described in Note 1 to the consolidated financial statements contained in this quarterly report on Form 10-Q. Information concerning our implementation and the impact of recent accounting standards issued by the
Financial Accounting Standards Board is included in the notes to our 2008 consolidated financial statements and also in Note 1 to the consolidated financial statements contained in this quarterly report on Form 10-Q. In addition, we believe the
following new accounting estimates reflect our more significant estimates and assumptions used in the preparation of our financial statements:

Valuation of the Embedded and Warrant Derivatives

The valuation of our embedded derivatives and warrant derivatives
are determined primarily by the Black-Scholes option pricing model. An embedded derivative is a derivative instrument that is embedded within another contract, which under the convertible note (the host contract), includes the right to convert the
note by the holder. In accordance with FASB Statement No. 133, FAS 133,Accounting for Derivative Instruments and Hedging Activities and EITF 07-5,Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entitys
Own Stock, these embedded derivatives are marked-to-market each reporting period, with a corresponding non-cash gain or loss charged to the current period. Based on FAS 133 and EITF 07-5, warrants which are determined to be classified as
derivative liabilities are marked-to-market each reporting period, with a corresponding non-cash gain or loss charged to the current period.

To determine the fair value of our embedded derivatives, management evaluates assumptions regarding the probability of certain future events. Other factors used to determine fair value include our period end stock price, historical stock
volatility, risk free interest rate and derivative term. The fair value recorded for the derivative liability varies from period to period.

Notes
receivable

As of June 30, 2009 we had notes receivable of approximately $12.9 million which represented 5.4% of our total
assets. Notes Receivables are also known as Bankers Acceptance Bills in China. Notes receivable are notes received from customers for the settlement of trade receivable balances. As of June 30, 2009, all notes receivables were issued by
established banks in the Peoples Republic of China and these notes are irrevocable, discountable and transferrable and have maturities of six months or less. The fair value of the notes receivable approximated their carrying value.



30



---

##### Table of Contents

Three months ended June 30, 2009 Compared to Three months ended June 30, 2008

The following table sets forth the amounts and the percentage relationship to revenues of certain items in our consolidated statements of income for the
three months ended June 30, 2009 and 2008:



|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|-------------------------------------- |  | ---------------------------------- | ------ | - | ---------------------------------- | - | ------ | ---- |  | ----- | ---- |  | ----- | -
|                                       |  | For the Three MonthsEnded June 30, |        |   | For the Three MonthsEnded June 30, |  
|($ amounts in thousands)               |  | 2009                               |        |   | 2008                               |   |        | 2009 |  |       | 2008 | 
|Net Revenues                           |  | $                                  | 32,483 |   |                                    | $ | 29,638 |      |  | 100.0 | %    |  | 100.0 | %
|Cost of Sales                          |  |                                    | 18,089 |   |                                    |   | 13,077 |      |  | 55.7  | %    |  | 44.1  | %
|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|Gross Margin                           |  |                                    | 14,394 |   |                                    |   | 16,561 |      |  | 44.3  | %    |  | 55.9  | %
|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|Sales and Marketing Expenses           |  |                                    | 10,300 |   |                                    |   | 11,138 |      |  | 31.7  | %    |  | 37.6  | %
|General and Administrative Expenses    |  |                                    | 4,001  |   |                                    |   | 3,819  |      |  | 12.3  | %    |  | 12.9  | %
|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|Total Operating Expenses               |  |                                    | 14,301 |   |                                    |   | 14,957 |      |  | 44.0  | %    |  | 50.5  | %
|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|Profit From Operations                 |  |                                    | 93     |   |                                    |   | 1,604  |      |  | 0.3   | %    |  | 5.4   | %
|Other Income (Expense):                |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|Interest Income                        |  |                                    | 84     |   |                                    |   | 14     |      |  | 0.3   | %    |  | 0.0   | %
|Interest Expense                       |  |                                    | (1,058 | ) |                                    |   | (1,611 | )    |  | -3.3  | %    |  | -5.4  | %
|Debt Issuance Cost Amortization        |  |                                    | (97    | ) |                                    |   | (210   | )    |  | -0.3  | %    |  | -0.7  | %
|Equity Method Investment Income        |  |                                    | 65     |   |                                    |   |       |      |  | 0.2   | %    |  | 0.0   | %
|Loss on Early Extinguishment of Debt   |  |                                    |       |   |                                    |   |       |      |  | 0.0   | %    |  | 0.0   | %
|Gain on Derivatives                    |  |                                    | (447   | ) |                                    |   |       |      |  | -1.4  | %    |  | 0.0   | %
|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|Total Other Expense                    |  |                                    | (1,453 | ) |                                    |   | (1,807 | )    |  | -4.5  | %    |  | -6.1  | %
|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|Loss Before Provision for Income Taxes |  |                                    | (1,360 | ) |                                    |   | (203   | )    |  | -4.2  | %    |  | -0.7  | %
|Provision for Income Taxes             |  |                                    | 372    |   |                                    |   | 1,064  |      |  | -1.1  | %    |  | -3.6  | %
|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  
|Net Loss                               |  | $                                  | (1,732 | ) |                                    | $ | (1,267 | )    |  | -5.3  | %    |  | -4.3  | %
|                                       |  |                                    |        |   |                                    |   |        |      |  |       |      |  |       |  

Net Revenues

Net revenue was approximately $32,483,000 for the three months ended June 30, 2009 as compared with approximately $29,638,000 for the three months ended June 30, 2008. Revenue by product categories was as
follows:



|                         |  |                             |        |                       |   |        |          |   |        |   |  |       |  
|------------------------ |  | --------------------------- | ------ | --------------------- | - | ------ | -------- | - | ------ | - |  | ----- | -
|                         |  | Three months ended June 30, |        | $ Increase/(Decrease) |   |        | % Change |  
|($ amounts in thousands) |  | 2009                        |        | 2008                  |   |       
|Branded OTC Sales        |  | $                           | 16,810 |                       | $ | 19,612 |          | $ | (2,802 | ) |  | -14.3 | %
|Distribution products    |  |                             | 14,122 |                       |   | 8,657  |          |   | 5,465  |   |  | 63.1  | %
|Licensed products        |  |                             | 1,551  |                       |   | 1,369  |          |   | 182    |   |  | 13.3  | %
|                         |  |                             |        |                       |   |        |          |   |        |   |  |       |  
|                         |  | $                           | 32,483 |                       | $ | 29,638 |          | $ | 2,845  |   |  | 9.6   | %
|                         |  |                             |        |                       |   |        |          |   |        |   |  |       |  

Branded OTC Sales. Sunstone revenues were $16,810,000 for the three months ended
June 30, 2009 as compared to $19,612,000 for the three months ended June 30, 2008. The top products were Pediatric Paracetamol and Amantadine Hydrochloride Granules, Pediatric Huatan Zhike Granules, Confort Pessaries, Pediatric Kechuanling
Oral Solution and Pidotimod Tablets which accounted for approximately 83.8% of Sunstones revenue for the period. This reduction in Sunstone revenues is due to the market uncertainty resulting from the upcoming health care reform in the
Peoples Republic of China. During the three months ended June 30, 2009, distributors reduced inventory on hand in an effort to acquire products in the future at a lower price, if the products are included in the Essential Drug List. The
Company believes inventory at distributors was reduced from six weeks sales to three weeks sales during the three months ended June 30, 2009.



31



---

##### Table of Contents

Distribution Products. Distribution revenue for the three months ended June 30, 2009,
excluding licensed products, was $14,122,000 as compared to $8,657,000 for the three months ended June 30, 2008, an increase of 63.1%. For the three months ended June 30, 2009 the results include Wanwei and Rongheng as compared to the
three months ended June 30, 2008 which only include the results of Wanwei. Rongheng was acquired in July 2008. Ronghengs top five products were Selenious Yeast Tablets, Iohexol, Gemcitabine Hydrochloride, Almitrine and Raubasine
compound and Cefotiam Hydrochloride, which collectively accounted for 24.5% of Ronghengs revenue for the three months, ended June 30, 2009. Wanweis top five products excluding our licensed products were Xingnaojing, Glurenorm,
Xuebijing, Ferrous Succinate Tablets, and Jinlong Capsule which collectively accounted for 38.2% of Wanweis revenue for the three months ended June 30, 2009. For the three months ended June 30, 2008 Wanweis top five products
accounted for 42.0% of total revenue.

Licensed Products. We provided sales and marketing and distribution services for Anpo and
Propess used in obstetrics, Galake for mild to moderate pain and Ferriprox for iron overload in patients with Thalassemia. Revenues totaled $1,551,000 for the three months ended June 30, 2009 as compared to $1,369,000 for the three months ended
June 30, 2008, an increase of 13.3%. As of June 30, 2009 there were 506 and 650 hospitals selling Propess and Anpo respectively, versus 452 and 481, respectively, as of June 30, 2008.

Cost of Goods Sold:



|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|------------------------ |  | --------------------------- | ------ | - | -------- | - | ------ | -------------------- |  | - | -------- | - |  | ----- | -
|                         |  | Three months ended June 30, |       
|($ amounts in thousands) |  | 2009                        |        |   | 2008 (1) |   |        | $ Increase(Decrease) |  |   | % Change |  
|Branded OTC              |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Revenues                 |  | $                           | 16,810 |   |          | $ | 19,612 |                      |  | $ | (2,802   | ) |  | -14.3 | %
|Cost of Sales            |  |                             | 4,115  |   |          |   | 4,294  |                      |  |   | (179     | ) |  | -4.2  | %
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Gross Profit             |  | $                           | 12,695 |   |          | $ | 15,318 |                      |  | $ | (2,623   | ) |  | -17.1 | %
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Gross Margin%            |  |                             | 75.5   | % |          |   | 78.1   | %                    |  |   |          |   |  |       |  
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Distribution (1)         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Revenues                 |  | $                           | 14,122 |   |          | $ | 8,657  |                      |  | $ | 5,465    |   |  | 63.1  | %
|Cost of Sales            |  |                             | 13,395 |   |          |   | 8,176  |                      |  |   | 5,219    |   |  | 63.8  | %
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Gross Profit             |  | $                           | 727    |   |          | $ | 481    |                      |  | $ | 246      |   |  | 51.1  | %
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Gross Margin%            |  |                             | 5.1    | % |          |   | 5.6    | %                    |  |   |          |   |  |       |  
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Licensed Products        |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Revenues                 |  | $                           | 1,551  |   |          | $ | 1,369  |                      |  | $ | 182      |   |  | 13.3  | %
|Cost of Sales            |  |                             | 579    |   |          |   | 607    |                      |  |   | (28      | ) |  | -4.6  | %
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Gross Profit             |  | $                           | 972    |   |          | $ | 762    |                      |  | $ | 210      |   |  | 27.6  | %
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Gross Margin%            |  |                             | 62.7   | % |          |   | 55.7   | %                    |  |   |          |   |  |       |  
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Total                    |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Revenues                 |  | $                           | 32,483 |   |          | $ | 29,638 |                      |  | $ | 2,845    |   |  | 9.6   | %
|Cost of Sales            |  |                             | 18,089 |   |          |   | 13,077 |                      |  |   | 5,012    |   |  | 38.3  | %
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Gross Profit             |  | $                           | 14,394 |   |          | $ | 16,561 |                      |  | $ | (2,167   | ) |  | -13.1 | %
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  
|Gross Margin%            |  |                             | 44.3   | % |          |   | 55.9   | %                    |  |   |          |   |  |       |  
|                         |  |                             |        |   |          |   |        |                      |  |   |          |   |  |       |  



|(1) | Revenues and cost of goods sold for the Distribution segment includes Wanwei for the three months ended June 30, 2009 and 2008 and Rongheng for the period April 1, 2009
through June 30, 2009.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cost of goods sold was approximately $18,089,000 for the three months ended June 30, 2009
as compared with $13,077,000 for the three months ended June 30, 2008. The gross profit for the three months ended June 30, 2009 was 44.3% as compared to 55.9% for the three months ended June 30, 2008. Cost of goods sold includes
Rongheng for the three months ended June 30, 2009. Rongheng was acquired in July 2008. The gross profit for the three months ended June 30, 2009 of Sunstone products was $12,695,000, which included $115,000 of amortization of intangibles
resulting from the Sunstone acquisition. The gross profit for the three months ended June 30, 2008 of Sunstone was $15,318,000, which included $107,000 of amortization of intangibles resulting from the Sunstone acquisition. The gross profit for
Sunstone was 75.5% for the three months ended June 30, 2009 as compared to 78.1% for the three moths ended June 30, 2008.



32



---

##### Table of Contents

The gross profit for the three months ended June 30, 2009 for distribution was $727,000 as compared
to $481,000 for the three months ended June 30, 2008. The gross margin for the distribution was 5.1% for the three months ended June 30, 2009 as compared to 5.6% for the three months ended June 30, 2008.

The gross profit for the three months ended June 30, 2009 for licensed products was $972,000 as compared to $762,000 for the three months ended
June 30, 2008. The gross margin for licensed products was 62.7% for the three months ended June 30, 2009 as compared to 55.7% for the three months ended June 30, 2008. The increase in gross margin was the result of the Companys
revenue mix changing to include a larger percentage of high gross profit products. In addition, the Company introduced a higher gross profit version of Propess in 2009.

Sales and Marketing Expenses:

Sales and marketing expenses were $10,300,000 for the three months
ended June 30, 2009 as compared with $11,138,000 for the three months ended June 30, 2008. Sales and marketing expenses include Rongheng for the three months ended June 30, 2009. Rongheng was acquired in July 2008. Selling and
Marketing expenses as a percentage of net revenues decreased to 31.7% for the three months ended June 30, 2009 as compared to 37.6% for the three months ended June 30, 2008. Advertising, travel and entertainment, marketing, salaries and
related benefits, selling expenses and amortization of intangibles account for $9,212,000 or 89.4% of sales and marketing expenses for the three months ended June 30, 2009 as compared to $10,062,000 or 90.3% for the three months ended
June 30, 2008. The most significant sales and marketing expense decreases for the three months ended June 30, 2009 as compared to the three months ended June 30, 2008 are as follows: marketing $1,555,000 and transportation $252,000.
Advertising increased $987,000 for the three months ended June 30, 2009 as compared to 2008. The changes in marketing and advertising expenses from 2008 to 2009 is the result of the timing of expenditures at Sunstone.

General and Administrative Expenses:

General and
administrative expenses were approximately $4,001,000 for the three months ended June 30, 2009 as compared to $3,819,000 for the three months ended June 30, 2008. General and administrative expenses include $97,000 for Rongheng for the
three months ended June 30, 2009. Rongheng was acquired in July 2008. General and administrative expenses as a percentage of net revenues decreased to 12.3% for the three months ended June 30, 2009 as compared to 12.9% for the three months
ended June 30, 2008. Salary and related expenses increased $325,000 for the three months ended June 30, 2009 as compared to the three months ended June 30, 2008 which was the result of Rongheng acquisition and the expansion of our
administrative and corporate staff in China. Research and development expenses increased $422,000 for the three months ended June 30, 2009 as compared to three months ended June 30, 2008. Office expenses decreased $233,000 for the three
months ended June 30, 2009 as compared to the three months ended June 30, 2008, which included receiving a $70,000 grant from the government for installing energy efficient cooling system. Business taxes decreased $265,000 for the three
months ended June 30, 2009 as compared to the three months ended June 30, 2008, which included receiving a VAT tax refund of $126,000 for purchasing domestic manufactured production equipment.

Interest Income:

Our interest income primarily
consists of income earned on our cash and cash equivalents and debt premium amortization. We received interest income on our balances of cash and cash equivalents of $46,000 during the three months ended June 30, 2009 and $14,000 for the three
months ended June 30, 2008. As of June 30, 2009, the unamortized debt premium amounted to $258,000. Total premium amortization was $38,000 for the three months ended June 30, 2009.

Interest Expense:

Our interest expense primarily
consists of incurred interest and debt discount amortization from our November 2007, January 2009 and March 2009 long term debt financings. We had interest expense of $1,058,000 for the three months ended June 30, 2009 and
$1,611,000 for the three months ended June 30, 2008, of which total amortization of debt discount was $0 for the three months ended June 30, 2009 as compared to $767,000 for the three months ended June 30, 2008.



33



---

##### Table of Contents

Debt Issuance Cost Amortization:

Our issuance cost amortization is the result of the long term debt financing costs we incurred in November 2007, January 2009 and March 2009. The Company defers debt issuance costs and amortizes the
amount over the life of debt on a straight-line basis which approximates the effective interest method. The unamortized debt issuance cost was $939,000 as of June 30, 2009 and $97,000 of debt issuance costs had been amortized for the three
months ended June 30, 2009 as compared to $210,000 for the three months ended June 30, 2008.

Loss on Derivatives:

The loss on derivative liability is in connection with the warrants which were issued as part of the common stock issuance as of February 2009. The loss
on derivatives was $447,000 for the three months ended June 30, 2009.

Equity Method Investment Income:

Our 50% investment in Shengda is included in our financial statements under the equity method of accounting for the three months ended June 30, 2009,
the difference between our cost of our investment and our proportionate share of the equity in the underlying net assets is accounted for under the purchase method of accounting. Under the purchase method of accounting we allocate the purchase price
to the net assets acquired in the transaction at their respective estimated fair market values.

The following table provides a
reconciliation of our equity method investment income. Prior to purchase accounting adjustments, Shengda generated net income of $334,000, or $167,000 for our 50% equity ownership. The total of amortization for the period was $102,000 which resulted
in an equity method investment income of $65,000.



|                                                                                                    |  |   |     |  
|--------------------------------------------------------------------------------------------------- |  | - | --- | -
|($ amounts in thousands)                                                                            |  |   |    
|Equity in earnings of Shengda for the three months ended June 30, 2009                              |  | $ | 167 |  
|Less adjustments of excess fair value:                                                              |  |   |     |  
|Inventory sold                                                                                      |  |   | (8  | )
|Depreciation and amortization expense of buildings and intangible assets, including land use rights |  |   | (94 | )
|                                                                                                    |  |   |     |  
|Total equity method investment income                                                               |  | $ | 65  |  
|                                                                                                    |  |   |     |  

Income Taxes

For the three months ended June 30, 2009, we recognized $372,000 of income tax expense on loss before income taxes of $1,289,000. This compared to income tax expense for the three months ended June 30, 2008
of $1,064,000 on loss before income taxes of $203,000. China does not permit the filing of a consolidated tax return for the entities that are wholly owned by the Company, which results in Sunstone having income tax expense on profit before income
taxes while the Companys has a consolidated loss before income taxes. Prior to December 2008 we recorded taxes at a rate of 25% for Sunstone. On December 3, 2008, Sunstone obtained the Hi-tech Enterprise Certificate issued by the
Hebei Science and Technology Department, which provides Sunstone with a preferential income tax rate of 15%. This designation entitled Sunstone to receive preferential treatment in 2008, 2009 and 2010 which reduced the income tax rate from 25% to
15%.



34



---

##### Table of Contents

Six Months Ended June 30, 2009 Compared to Six Months Ended June 30, 2008

The following table sets forth the amounts and the percentage relationship to revenues of certain items in our consolidated statements of
income for the six months ended June 30, 2009 and 2008:



|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|-------------------------------------- |  | -------------------------------- | ------ | - | -------------------------------- | - | ------ | ---- |  | ----- | ---- |  | ----- | -
|                                       |  | For the Six Months EndedJune 30, |        |   | For the Six Months EndedJune 30, |  
|($ amounts in thousands)               |  | 2009                             |        |   | 2008                             |   |        | 2009 |  |       | 2008 | 
|Net Revenues                           |  | $                                | 71,746 |   |                                  | $ | 47,727 |      |  | 100.0 | %    |  | 100.0 | %
|Cost of Sales                          |  |                                  | 36,694 |   |                                  |   | 23,445 |      |  | 51.1  | %    |  | 49.1  | %
|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|Gross Profit                           |  |                                  | 35,052 |   |                                  |   | 24,282 |      |  | 48.9  | %    |  | 50.9  | %
|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|Sales and Marketing Expenses           |  |                                  | 23,811 |   |                                  |   | 17,099 |      |  | 33.2  | %    |  | 35.8  | %
|General and Administrative Expenses    |  |                                  | 7,930  |   |                                  |   | 6,975  |      |  | 11.1  | %    |  | 14.6  | %
|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|Total Operating Expenses               |  |                                  | 31,741 |   |                                  |   | 24,074 |      |  | 44.3  | %    |  | 50.4  | %
|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|Profit (Loss) From Operations          |  |                                  | 3,311  |   |                                  |   | 208    |      |  | 4.6   | %    |  | 0.4   | %
|Other Income (Expense):                |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|Interest Income                        |  |                                  | 108    |   |                                  |   | 62     |      |  | 0.2   | %    |  | 0.1   | %
|Interest Expense                       |  |                                  | (2,475 | ) |                                  |   | (3,180 | )    |  | -3.4  | %    |  | -6.7  | %
|Debt Issuance Cost Amortization        |  |                                  | (225   | ) |                                  |   | (420   | )    |  | -0.3  | %    |  | -0.9  |  
|Equity Method Investment Income        |  |                                  | 82     |   |                                  |   | 675    |      |  | 0.1   | %    |  | 1.4   | %
|Loss on Early Extinguishment of Debt   |  |                                  | (4,573 | ) |                                  |   |       |      |  | -6.4  | %    |  |      |  
|Gain on Derivatives                    |  |                                  | 1,204  |   |                                  |   |       |      |  | 1.7   | %    |  |      |  
|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|Total Other Income (Expense)           |  |                                  | (5,879 | ) |                                  |   | (2,863 | )    |  | -8.1  | %    |  | -6.0  | %
|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|Loss Before Provision for Income Taxes |  |                                  | (2,568 | ) |                                  |   | (2,655 | )    |  | -3.5  | %    |  | -5.6  | %
|Provision for Income Taxes             |  |                                  | 1,154  |   |                                  |   | 1,411  |      |  | -1.6  | %    |  | 3.0   |  
|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  
|Net Loss                               |  | $                                | (3,722 | ) |                                  | $ | (4,066 | )    |  | -5.1  | %    |  | -8.5  | %
|                                       |  |                                  |        |   |                                  |   |        |      |  |       |      |  |       |  

Net Revenues:

Net revenues were approximately $71,746,000 for the six months ended June 30, 2009 as compared with approximately $47,727,000 for the six months ended June 30, 2008. Sunstone revenues were included for the
period February 18, 2008 through June 30, 2008.

Revenue by product categories was as follows:



|                         |  |                           |        |      |   |            |  |          |        |  |      |  
|------------------------ |  | ------------------------- | ------ | ---- | - | ---------- |  | -------- | ------ |  | ---- | -
|                         |  | Six Months Ended June 30, |       
|($ amounts in thousands) |  | 2009                      |        | 2008 |   | $ Increase |  | % Change |       
|Branded OTC              |  | $                         | 41,337 |      | $ | 29,069     |  | $        | 12,268 |  | 42.2 | %
|Distribution products    |  |                           | 27,506 |      |   | 16,092     |  |          | 11,414 |  | 70.9 | %
|Licensed products        |  |                           | 2,903  |      |   | 2,566      |  |          | 337    |  | 13.1 | %
|                         |  |                           |        |      |   |            |  |          |        |  |      |  
|                         |  | $                         | 71,746 |      | $ | 47,727     |  | $        | 24,019 |  | 50.3 | %
|                         |  |                           |        |      |   |            |  |          |        |  |      |  

Branded OTC. Sunstone revenues were $41,337,000 for the six months ended June 30, 2009
as compared to $29,069,000 for the period February 18, 2008 through June 30, 2008, an increase of 42.2%. Sunstone manufactures and sells pediatric products under the Goodbaby brand, womens health products under the Confort brand and
nutritional products under the Nemei brand. The Goodbaby franchise accounted for 82.4% of Sunstones total product sales for the six months ended June 30, 2009 as compared to 84.0% for the period February 18, 2008 through
June 30, 2008. The top products were Pediatric Paracetamol and Amantadine Hydrochloride Granules for the treatment of the common cold, Pediatric Huatan Zhike Granules for the treatment of coughing, Pediatric



35



---

##### Table of Contents

Kechuanling Oral Solution for the treatment of coughing and Pidotimod Tablets for pediatric diarrhea. These top five products accounted for approximately
87.5% of Sunstones revenue for the six months ended June 30, 2009 as compared to 88.0% of Sunstones revenue for the period February 18, 2008 through June 30, 2008.

Distribution Products. Distribution revenue for the six months ended June 30, 2008, excluding licensed products, was $27,506,000 as compared
to $16,092,000 for the six months ended June 30, 2008, an increase of 70.9%. For the six months ended June 30, 2009, the results include Wanwei and Rongheng as compared to the six months ended June 30, 2008, which only includes the
results of Wanwei. Rongheng was acquired July 2008. Wanweis top five products were Xingnaojing, Glurenorm, Xuebijing, Ferrous Succinate Tablets, and Jinlong capsules, which accounted for 36.8% of total distribution revenue for the six months
ended June 30, 2009 as compared to 40.0% for the six months ended June 30, 2008. Ronghengs top five products were Selenious Yeast Tablets, Iohetol, Gemeitabine Hydrochloride, Almitrine and Raubasine compound and Celotiam
Hydrochloride, which collectively accounted for 24.5% of Ronghengs revenue for the six months ended June 30, 2009.

Licensed
Products. We provided sales and marketing and distribution services for Anpo, Propess, Galake and Ferriprox with revenue of $2,903,000 for the six months ended June 30, 2009 as compared to $2,566,000 for the six months ended June 30,
2008, an increase of 13.1%. This increase was the result of continued sales and marketing efforts promoting Propess, Anpo, Galake and initiating sales of Ferriprox in the third quarter of 2008. As of June 30, 2009 there were 506 and 650
hospitals selling Propess and Anpo respectively, versus 452 and 481 as of June 30, 2008.

Cost of Sales:



|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|------------------------ |  | ------------------------- | ------ | - | ---- | - | ------ | --------------------- |  | - | -------- | - |  | ----- | -
|                         |  | Six Months Ended June 30, |       
|($ amounts in thousands) |  | 2009                      |        |   | 2008 |   |        | $ Increase/(Decrease) |  |   | % Change |  
|Branded OTC (1)          |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Revenues                 |  | $                         | 41,337 |   |      | $ | 29,069 |                       |  | $ | 12,268   |   |  | 42.2  | %
|Cost of Sales            |  |                           | 9,856  |   |      |   | 7,035  |                       |  |   | 2,821    |   |  | 40.1  | %
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Gross Profit             |  | $                         | 31,481 |   |      | $ | 22,034 |                       |  | $ | 9,447    |   |  | 42.9  |  
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Gross Margin%            |  |                           | 76.2   | % |      |   | 75.8   | %                     |  |   |          |   |  |       |  
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Distribution (2)         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Revenues                 |  | $                         | 27,506 |   |      | $ | 16,092 |                       |  | $ | 11,414   |   |  | 70.9  | %
|Cost of Sales            |  |                           | 25,690 |   |      |   | 15,258 |                       |  |   | 10,432   |   |  | 68.4  | %
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Gross Profit             |  | $                         | 1,816  |   |      | $ | 834    |                       |  | $ | 982      |   |  | 117.7 | %
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Gross Margin%            |  |                           | 6.6    | % |      |   | 5.2    | %                     |  |   |          |   |  |       |  
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Licensed Products        |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Revenues                 |  | $                         | 2,903  |   |      | $ | 2,566  |                       |  | $ | 337      |   |  | 13.1  | %
|Cost of Sales            |  |                           | 1,148  |   |      |   | 1,152  |                       |  |   | (4       | ) |  | -0.3  | %
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Gross Profit             |  | $                         | 1,755  |   |      | $ | 1,414  |                       |  | $ | 341      |   |  | 24.1  | %
|Gross Margin%            |  |                           | 60.5   | % |      |   | 55.1   | %                     |  |   |          |   |  |       |  
|Total                    |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Revenues                 |  | $                         | 71,746 |   |      | $ | 47,727 |                       |  | $ | 24,019   |   |  | 50.3  | %
|Cost of Sales            |  |                           | 36,694 |   |      |   | 23,445 |                       |  |   | 13,249   |   |  | 56.5  | %
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Gross Profit             |  | $                         | 35,052 |   |      | $ | 24,282 |                       |  | $ | 10,770   |   |  | 44.4  | %
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  
|Gross Margin%            |  |                           | 48.9   | % |      |   | 50.9   | %                     |  |   |          |   |  |       |  
|                         |  |                           |        |   |      |   |        |                       |  |   |          |   |  |       |  



|(1) | Revenue and cost of sales for the Sunstone OTC segment is for the period February 18, 2008 through June 30, 2008.
|--- | -----------------------------------------------------------------------------------------------------------------



|(2) | Revenue and cost of sales for Distribution includes Wanwei for the six months ended June 30, 2009 and 2008 and Rongheng for the six months ended June 30, 2009.
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------



36



---

##### Table of Contents

Cost of goods sold was approximately $36,694,000 for the six months ended June 30, 2009 as compared
with $23,445,000 for the six months ended June 30, 2008. The gross profit for the six months ended June 30, 2009 was 48.9% as compared to 50.9% for the six months ended June 30, 2008. The gross profit of Sunstone products for the six
months ended June 30, 2009 was $31,481,000, which included $230,000 of purchase accounting adjustment of amortization of intangibles resulting from the Sunstone acquisition. The gross margin for the six months ended June 30, 2009 was 76.2%
as compared to 75.8% for the six months ended June 30, 2008.

The gross profits for the six months ended June 30, 2009 for
distribution was $1,816,000 as compared to $834,000 for the six months ended June 30, 2008. The gross margin for distribution products was 6.6% for the six months ended June 30, 2009 as compared to 5.2% for the six months ended
June 30, 2008.

The gross profits for the six months ended June 30, 2009 for licensed products was $1,755,000 as compared to
$1,414,000 for the six months ended June 30, 2008. The gross margin for licensed products was 60.5% for the six months ended June 30, 2009 as compared to 55.1% for the six months ended June 30, 2008. The increase in gross margin was
the result of the Companys revenue mix changing to include a larger percentage of high gross profit products. In addition, the Company introduced a higher gross profit version of Propess in 2009.

Sales and Marketing Expenses:

Sales and marketing
expenses were $23,811,000 for the six months ended June 30, 2009 as compared with $17,099,000 for the six months ended June 30, 2008. Marketing, advertising, salaries and related benefits, office expenses, travel and entertainment and
amortization of intangibles account for $21,087,000 or 88.6% of sales and marketing expenses for the six months ended June 30, 2009 as compared to $14,958,000 or 87.5% of sales and marketing expenses for the six months ended June 30, 2008.
The most significant sales and marketing expense increases for the six months ended June 30, 2009 as compared to the six months ended June 30, 2008 were the result of the Sunstone included for six months ended June 30, 2009 as compared to
the period February 18, 2008 through June 30, 2008 and are as follows: advertising of $3,595,000; salaries and related benefits of $470,000; sales office selling expenses of $880,000; travel and entertainment of $1,468,000 and amortization of
intangibles of $240,000 which resulted from the acquisition of Sunstone.

General and Administrative Expenses:

General and administrative expenses were approximately $7,930,000 for the six months ended June 30, 2009 as compared to $6,975,000 for the six months
ended June 30, 2008. As a percentage of net revenues general and administrative expenses decreased to 11.1% for the six months ended June 30, 2009 as compared to 14.6% for the six months ended June 30, 2008. Salaries and related
benefits increased $499,000 for the six months ended June 30, 2009 as compared to the six months ended June 30, 2008. This increase is the result of the Sunstone and Rongheng acquisitions during 2008, the increase in additional senior
management in China in 2008 and salary increases and expansion of our administrative and corporate staff in China in 2008. Professional fees increased $178,000 for the six months ended June 30, 2009 as compared to the six months ended
June 30, 2008. This increase is the result of the Rongheng and Sunstone acquisitions and the sale of Alliance BMP Limited. Research and development increased $390,000 for the six months ended June 30, 2009 as compared to the six months
ended June 30, 2008. State and business taxes decreased $242,000 for the six months ended June 30, 2009 as compared to June 30, 2008.

Interest Income:

Our interest income primarily consists of income earned on our cash and cash equivalents and debt premium
amortization. We received interest income on our balances of cash and cash equivalents of $63,000 during the six months ended June 30, 2009 and $12,000 for the six months ended June 30, 2008. As of June 30, 2009, the unamortized debt
premium amounted to $258,000. Total premium amortization was $45,000 for the six months ended June 30, 2009.

Interest Expense:

Our interest expense primarily consists of incurred interest and debt discount amortization from our November 2007, January 2009 and March 2009 long
term debt financings. We had interest expenses of 2,475,000 for the six months ended June 30, 2009 and $3,180,000 for the six months ended June 30, 2008, of which amortization of debt discount was $450,000 for the six months ended
June 30, 2009 and $1,534,000 for the six months ended June 30, 2008.



37



---

##### Table of Contents

Debt Issuance Cost Amortization:

Our issuance cost amortization is the result of the long term debt financing costs we incurred in November 2007, January 2009 and March 2009. The Company defers debt issuance costs and amortizes the amount over
the life of debt on a straight-line basis which approximates the effective interest method. The unamortized debt issuance cost was $939,000 as of June 30, 2009 and $225,000 of debt issuance costs had been amortized for the six months ended
June 30, 2009 as compared to $420,000 for the six months end June 30, 2008.

Equity Method Investment Income:

Our 50% investment in Shengda is included in our financial statements under the equity method of accounting for the period February 16, 2009 through
June 30, 2009, the difference between our cost of our investment and our proportionate share of the equity in the underlying net assets is accounted for under the purchase method of accounting. Under the purchase method of accounting we
allocate the purchase price to the net assets acquired in the transaction at their respective estimated fair market values.

The following
table provides a reconciliation of our equity method investment income. Prior to purchase accounting adjustments, Shengda generated net income of $474,000, or $237,000 for our 50% equity ownership. The total of amortization for the period was
$155,000 which resulted in an equity method investment income of $82,000.



|                                                                                                    |  |                         |     |  
|--------------------------------------------------------------------------------------------------- |  | ----------------------- | --- | -
|                                                                                                    |  | ($ amounts inthousands) |    
|Equity in earnings of Shengda for period February 16 through June 30, 2009                          |  | $                       | 237 |  
|Less adjustments of excess fair value:                                                              |  |                         |     |  
|Inventory sold                                                                                      |  |                         | (61 | )
|Depreciation and amortization expense of buildings and intangible assets, including land use rights |  |                         | (94 | )
|                                                                                                    |  |                         |     |  
|Total equity method investment income                                                               |  | $                       | 82  |  

Our 49% investment in Sunstone China was included in our financial statements under the equity
method of accounting for the period January 1, 2008 through February 17, 2008, the difference between our cost of our investment and our proportionate share of the equity in the underlying net assets is accounted for under the purchase
method of accounting. The excess cost over book value of net assets acquired not representing trademarks and goodwill is amortized over the estimated useful life of acquired assets (with definitive useful lives) against our share of investee
earnings.

The following table provides a reconciliation of our equity method investment loss. Prior to purchase accounting adjustments
Sunstone China generated net income of $2,104,000 or $1,031,000 for our 49% equity ownership. The total amortization for the period was $356,000 which resulted in an equity method investment income of $675,000.



|                                                                                              |  |                         |       |  
|--------------------------------------------------------------------------------------------- |  | ----------------------- | ----- | -
|                                                                                              |  | ($ amounts inthousands) |      
|Equity in earnings of Sunstone China for the period January 1, 2008 through February 17, 2008 |  | $                       | 1,031 |  
|Less adjustments of excess fair value:                                                        |  |                         |       |  
|Amortization expense of intangible assets                                                     |  |                         | (356  | )
|                                                                                              |  |                         |       |  
|Total equity method investment gain after amortization                                        |  | $                       | 675   |  
|                                                                                              |  |                         |       |  

Loss on Early Extinguishment of Debt:

During the six months ended June 30, 2009, the Company recorded a loss of approximately $4,573,000 in deferred loan costs, debt discount and debt
premium, relative to the early extinguishment of debt under the previously outstanding long term debt.



38



---

##### Table of Contents

Gain on Derivatives:

The gain on derivatives liability is in connection with the convertible notes issued in January 2009, which were amended in March 2009 and May 2009, and the warrants which were issued as part of the common stock
issuance in February 2009. The gain on derivatives was $1,204,000 for the six months ended June 30, 2009.

Income Taxes:

For the six months ended June 30, 2009, we recognized $1,154,000 of income tax expense on loss before taxes of $2,497,000. This compared to income
tax expense for the six months ended June 30, 2008 of $1,411,000 on loss before taxes of 2,334,000.

China does not permit the filing
of a consolidated tax return for the entities that are wholly owned by the Company, which results in Sunstone having income tax expense on profit before income taxes while the Companys has a consolidated loss before income taxes. Prior to
December 2008 we recorded taxes at a rate of 25% for Sunstone. On December 3, 2008, Sunstone obtained the Hi-tech Enterprise Certificate issued by the Hebei Science and Technology Department, which provides Sunstone with a preferential
income tax rate of 15%. This designation entitled Sunstone to receive preferential treatment in 2008, 2009 and 2010 which reduced the income tax rate from 25% to 15%.



39



---

##### Table of Contents

|ITEM 3. | Quantitative and Qualitative Disclosures About Market Risk
|------- | ----------------------------------------------------------

Foreign Exchange Rate Sensitivity

We are exposed to cash flow and earnings fluctuations resulting from foreign
exchange rate variation because our operations are in China. This exposure arises from the translation of financial statements of our foreign subsidiaries BMP China, Sunstone and Wanwei, from RMB, the functional currency of China, into United States
dollars, our functional currency. For additional information on the risks associated with the RMB, see Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2008 Risk Factors  Risks Related to Doing Business
in China  Fluctuations in the Chinese Renminbi could adversely affect our results of operations.

We do not, as a routine
matter, use hedging vehicles to manage foreign exchange exposures. As of June 30, 2009, a 10% unfavorable change in the foreign exchange rates affecting balance sheet transactional exposures would have resulted in a reduction in pre-tax loss of
approximately $0.6 million. This hypothetical reduction on transactional exposure is based on the difference between June 30, 2009 actual foreign exchange rates and hypothetical rates assuming a 10% unfavorable change in foreign exchange
rates on that date.

The translation of the balance sheets of our Chinese operations from RMB into U.S. dollars is sensitive to changes in
foreign exchange rates. These translation gains or losses are recorded as translation adjustments within shareholders equity on our balance sheet. Using the example above, the hypothetical change in translation adjustments would be calculated
by multiplying the net assets of our Chinese operations by a 10% unfavorable change in the applicable foreign exchange rates. As of June 30, 2009, our analysis indicated that these hypothetical changes would reduce shareholders equity by
approximately $5.7 million or 3.8% of our June 30, 2009 shareholder equity of $150.9 million.

Interest Rate Sensitivity

We invest in high-quality financial instruments, primarily money market funds, federal agency notes, corporate debt securities,
bank certificates of deposit, commercial paper and United States treasury notes, which we believe are subject to limited credit risk. We currently do not hedge interest rate exposure. Due to the short-term nature of our investments, we do not
believe that we have any material exposure to interest rate risk arising from our investments.



40



---

##### Table of Contents

|ITEM 4. | Controls and Procedures
|------- | -----------------------

(a) Evaluation of Disclosure
Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated
the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
as of the end of the period covered by this report were functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized
and reported within the time periods specified in the SECs rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely
decisions regarding disclosure. A controls system cannot provide absolute assurance, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if
any, within a company have been detected.

(b) Changes in Internal Control Over Financial Reporting

No change in our internal control over financial reporting occurred during our second fiscal quarter that materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.



41



---

##### Table of Contents

PART II  OTHER INFORMATION



|ITEM 1A. | Risk Factors.
|-------- | -------------

In addition to the other information
contained in this report, you should carefully consider the risk factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2008, which could materially affect our
business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may
materially adversely affect our business, financial condition and/or operating results.



42



---

##### Table of Contents

|ITEM 4. | Submission of Matters to a Vote of Security Holders.
|------- | ----------------------------------------------------



|(a) | The Annual Meeting of the Stockholders of the Company was held on April 27, 2009.
|--- | ---------------------------------------------------------------------------------



|(b) | All director nominees were elected. The directors elected at the meeting were David (Xiaoying) Gao, Martyn D. Greenacre, Jack M. Ferraro, Zhiqiang Han, Frank Hollendoner, John W.
Stakes, Zhijun Tong and Albert Yeung.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(c) | Certain matters voted upon at the meeting and the votes cast with respect to such matters are as follows:
|--- | ---------------------------------------------------------------------------------------------------------



|                      |  |            |  |         |  |        
|--------------------- |  | ---------- |  | ------- |  | -------
|                      |  | For        |  | Against |  | Abstain
|Election of Directors |  |            |  |         |  |        
|David (Xiaoying) Gao  |  | 33,502,302 |  | *       |  | 100,794
|Martyn D. Greenacre   |  | 32,868,157 |  | *       |  | 734,919
|Jack M. Ferraro       |  | 33,251,557 |  | *       |  | 351,539
|Zhiqiang Han          |  | 33,495,320 |  | *       |  | 107,776
|Frank Hollendoner     |  | 33,247,409 |  | *       |  | 355,687
|John W. Stakes        |  | 32,730,296 |  | *       |  | 872,800
|Zhijun Tong           |  | 33,479,458 |  | *       |  | 123,638
|Albert Yeung          |  | 33,478,998 |  | *       |  | 124,098



|* | Not applicable
|- | --------------

Ratification of the appointment of Grant Thornton LLP as
the Companys independent registered public accounting firm for the fiscal year ending December 31, 2009.



|           |  |         |  |        
|---------- |  | ------- |  | -------
|For        |  | Against |  | Abstain
|33,570,034 |  | 7,671   |  | 25,390 



43



---

##### Table of Contents

|ITEM 6. | Exhibits.
|------- | ---------



|      |  |                                                                                                                                                                                                                                                                                                                                                                                 
|----- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|10.1  |  | Form of Allonge to 12.5% Subordinated Convertible Note, as entered into on April 15, 2009, by and between BMP Sunstone Corporation and holders of BMP Sunstone Corporations 12.5%
Subordinated Convertible Notes due July 1, 2011 (incorporated by reference to Exhibit 10.1 of the registrants Current Report on Form 8-K filed on April 16, 2009)                           
|      | 
|10.2  |  | First Supplemental Indenture, as entered into on April 15, 2009, by BMP Sunstone Corporation and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit 10.2 of the
registrants Current Report on Form 8-K filed on April 16, 2009                                                                                                                      
|      | 
|10.3  |  | Form of Third Agreement to Amend 12.5% Secured Convertible Notes due July 1, 2011, as entered into on May 14, 2009, by BMP Sunstone Corporation and certain holders of BMP Sunstone
Corporations 12.5% Secured Convertible Notes due July 1, 2011 (incorporated by reference to Exhibit 10.1 of the registrants Current Report on Form 8-K filed on May 19, 2009)             
|      | 
|10.4  |  | Form of Agreement to Amend 12.5% Secured Convertible Notes due July 1, 2011, as entered into on May 14, 2009, by BMP Sunstone Corporation and certain holders of BMP Sunstone Corporations
12.5% March Exchange Secured Convertible Notes due July 1, 2011 (incorporated by reference to Exhibit 10.2 of the registrants Current Report on Form 8-K filed on May 19, 2009)    
|      | 
|10.5  |  | Form of Second Agreement to Amend 12.5% Secured Convertible Notes due July 1, 2011, as entered into on May 14, 2009, by BMP Sunstone Corporation and a certain holder of BMP Sunstone
Corporations 12.5% March Cash Secured Convertible Notes due July 1, 2011 (incorporated by reference to Exhibit 10.3 of the registrants Current Report on Form 8-K filed on May 19, 2009)
|      | 
|10.6  |  | Form of Second Allonge, as entered into on May 14, 2009, by BMP Sunstone Corporation and holders of BMP Sunstone Corporations 12.5% Subordinated Convertible Notes due July 1, 2011
(incorporated by reference to Exhibit 10.4 of the registrants Current Report on Form 8-K filed on May 19, 2009)                                                                           
|      | 
|10.7  |  | Second Supplemental Indenture, as entered into on May 14, 2009, by BMP Sunstone Corporation and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit 10.5 of the
registrants Current Report on Form 8-K filed on May 19, 2009)                                                                                                                        
|      | 
|31.1* |  | Certificate of the Chief Executive Officer of BMP Sunstone Corporation required by Rule 13a-14(a) under the Exchange Act.                                                                                                                                                                                                                                                       
|      | 
|31.2* |  | Certificate of the Chief Financial Officer of BMP Sunstone Corporation required by Rule 13a-14(a) under the Exchange Act                                                                                                                                                                                                                                                        
|      | 
|32.1* |  | Certificate of the Chief Executive Officer of BMP Sunstone Corporation required by Rule 13a-14(b) under the Exchange Act                                                                                                                                                                                                                                                        
|      | 
|32.2* |  | Certificate of the Chief Financial Officer of BMP Sunstone Corporation required by Rule 13a-14(b) under the Exchange Act                                                                                                                                                                                                                                                        



|* | Filed herewith.
|- | ---------------



44



---

##### Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



|                      |  |  |  |                                                                                    
|--------------------- |  |  |  | -----------------------------------------------------------------------------------
|                      |  |  |  | BMP SUNSTONE Corporation                                                           
|                      |  | 
|Date: August 10, 2009 |  |  |  | /s/ DAVID GAO                                                                      
|                      |  |  |  | David Gao Chief Executive Officer (Principal Executive Officer)                    
|                      |  | 
|Date: August 10, 2009 |  |  |  | /s/ FRED M. POWELL                                                                 
|                      |  |  |  | Fred M. Powell Chief Financial Officer (Principal Financial and Accounting Officer)



45